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ABSTRACT OF THESIS

BIOLOGY AND DETECTION OF PREGNANES DURING LATE GESTATION IN
THE MARE

Progesterone in the mare declines to almost undetectable concentrations in late gestation.
It’s metabolized into several pregnanes, some circulating at very high concentrations.
Although the function of many pregnanes remains unclear, 5α-dihydroprogesterone and
allopregnanolone are bioactive.

Measurements of pregnanes in late gestation are

typically by immunoassay, although results are confounded by cross-reactivity with
related pregnanes. Conversely, liquid chromatography tandem mass spectrometry (LCMS/MS) allows differentiation of individual pregnanes. The purposes of these studies
were: 1) to evaluate the ability of a 5α-reductase inhibitor, dutasteride, to alter pregnane
metabolism and pregnancy outcome, 2) to evaluate changes in target pregnanes in late
gestation by LC-MS/MS in mares with ascending placentitis, and 3) compare
immunoassay and LC-MS/MS detection of pregnanes in late gestation. Our findings
suggest that dutasteride significantly altered pregnane metabolism without effects on
pregnancy outcome. Pregnane measurement by LC-MS/MS resulted in a significant
(p<0.05) increase in pregnanes metabolized in the placenta, but not those coming directly
from the fetus in mares with placentitis. Results indicate pregnane profiles of mares with

chronic placentitis mirror those of healthy pregnancies prior to parturition. A comparison
of immunoassays demonstrated significant (p<0.05) differences in assay results, while
correlation was observed between immunoassay measurements and actual progesterone
concentrations by LC-MS/MS. These studies demonstrate the complexity of pregnane
metabolism in late gestation in the mare and the necessity of LC-MS/MS to detect
specific changes that immunoassays cannot differentiate.
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Chapter One: Introduction and objectives
Late gestation in the mare is unique in relation to most other mammalian species, which
rely on progesterone (P4) for pregnancy maintenance throughout gestation [1].
Progesterone in the latter half of gestation is at concentrations of <1.0 ng/mL in the mare
[2, 3].

P4 is metabolized into several pregnanes in the placenta [4] which can be

measured in the periphery of the mare’s circulation.
Changes in total pregnanes by immunoassay have been studied to indicate possible issues
with the fetus or placenta [5, 6], and immunoassays have been a useful tool in diagnosing
pregnancy complications. However, these assays are most often used in late gestation
(>300 days) when pregnancy compromise could result in an aborted fetus or
complications for the mare. Due to the time in which they are used, cross-reactions are
problematic [7]. The use of liquid chromatography tandem mass spectrometry (LCMS/MS) or gas chromatography mass spectrometry (GC-MS) has allowed the study of
individual pregnanes throughout gestation in healthy and compromised equine
pregnancies and assay results cannot give information beyond changes in total pregnane
concentrations. Further, multiple P4 antibodies are available for use in assays, and
discrepancies among results demonstrate a need for a standard method in hormone
measurement in the mare [8].
The use of liquid chromatography tandem mass spectrometry (LC-MS/MS) or gas
chromatography mass spectrometry (GC-MS) has allowed the study of individual
pregnanes throughout gestation in the healthy and compromised equine pregnancy [9-12].
In addition to individual pregnane measurement, tissue incubations have demonstrated
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that at least three pregnanes, 5α-dihydroprogesterone (DHP), 20α-hydroxy-5α-pregnan-3one (20α5P), and 5α-pregnane-3β,20α-diol (βα-diol) bind the equine progesterone
receptor [9, 12, 13]. This suggests their bioactivity in late gestation when P4 is nearly
undetectable.

Allopregnanolone has also demonstrated bioactivity, acting through

GABAA receptors to maintain fetal quiescence [14, 15]. Other quantitatively important
pregnanes include 3β-hydroxy-5α-pregnan-20-one (3β5P) and 5α-pregnane-3β,20β-diol
(ββ-diol), and these can reach concentrations of approximately 30-300 ng/mL in late
gestation [11].
Studies attempting to inhibit enzyme activity, necessary for pregnane metabolism, have
benefited from the ability to measure specific pregnanes and report changes associated
with enzyme disruption [16, 17]. Additionally, GC-MS has been used to identify changes
in individual pregnanes, as they relate to pregnancy disease or other pregnancy
complications from clinical cases [11]. To date, however, establishment of changes in
pregnanes which may be associated with a specific pregnancy complication has not been
reported in a controlled experiment.
The objectives for the studies in this thesis are as follows; 1) to investigate the effects of a
type 1 5α-reductase inhibitor (dutasteride) on pregnane metabolism and pregnancy
outcome in a set of healthy mares in late gestation, 2) to identify changes in a set of target
pregnanes (P5, P4, DHP, allopregnanolone, 20α5P, 3β5P, βα-diol, and ββ-diol) from
mares with experimentally induced ascending placentitis compared to a group of mares
with normal pregnancies 3) to compare results from multiple progesterone immunoassays
to actual P4 and DHP results by LC-MS/MS, and 4) to evaluate cross-reactions of P4, P5,
DHP, allopregnanolone, and altrenogest with multiple immunoassays.
2

Chapter two: Literature review
This review will focus on pregnanes (steroid hormones within the progesterone family)
and progestogens (21-carbon, steroid hormones that have progesterone-like activity and
are able to bind progesterone receptors) with an emphasis on normal and abnormal
profiles in late gestation in the mare. A healthy pregnancy in the mare is dependent on a
number of factors; one of them being the production and equilibration of steroid
hormones, including pregnanes [10, 18]. During the typical 340 day gestation (range
320-360 days) [19], a unique pregnane profile has been characterized in the mare [10].
The best known pregnane, progesterone (P4), begins to rise shortly after ovulation [20],
and continues to rise until approximately 80 days of gestation [10]. However, a healthy
pregnancy in the mare does not depend upon P4 alone [12, 16]. In fact, P4 levels begin
to decline around 100 days of gestation and are often undetectable in late gestation [2, 3,
10].

During this time, other pregnanes increase in concentration, including 5α-

dihydroprogesterone (DHP) and allopregnanolone which are believed to play a role in
pregnancy maintenance [9, 12, 15]. Production of these pregnanes ultimately depends on
a number of enzymes in the feto-placental unit [4, 21].

In cases of compromised

pregnancies, pregnane concentrations may be altered, making progesterone assays a
possible diagnostic tool [7]. However, the most common P4 assay, the enzyme linked
immunosorbent assay (ELISA), fails to give specific information on individual pregnanes
because there is a high incidence of cross-reactivity between different pregnanes within
these assays [22].

Therefore, results from liquid chromatography tandem mass

spectrometry (LC-MS/MS) or gas chromatography mass spectrometry (GS/MS) are
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useful to better understand changes in specific pregnane in both normal and abnormal
pregnancy [11].
Pregnanes in late gestation in healthy pregnancies
Measurable pregnanes and progestogens in the mare’s blood are the products of a
complex relationship with the fetus and the utero-placental tissues, commonly called the
feto-placental unit [4]. Pregnenolone (P5) is the primary precursor for downstream
pregnanes [23, 24], and P5 is produced by the fetus. Though some speculation exists
regarding its exact origin [25], P5 is believed to be primarily synthesized within the fetal
adrenal cortex with likely contributions from the fetal gonad. It is known that P5 is
synthesized from cholesterol by cytochrome P450scc, and immunostaining for P450scc
in the equine fetal adrenal gland indicated localization in the zona glomerulosa, zona
reticularis, and zona fasciculata of the adrenal cortex, with increasing abundance through
gestation [26]. Further evidence for the production of P5 in the fetal adrenal cortex is the
increase in maternal pregnane concentrations with intra-fetal administration of ACTH
[27]. Early work from MacArthur et al., suggested the presence of P450scc in the fetal
gonad by incubating the testis with sodium acetate in vitro, ultimately observing
androgens dependent on the enzyme [28]. However, studies in which fetal gonads were
removed during pregnancy did not yield changes to concentrations in maternal pregnanes
by immunoassay [29], leading to the suggestion that the fetal adrenal gland is the primary
source for P5 synthesis.
Pregnenolone concentrations rise steadily from approximately 0.5 ng/mL in week 18,
peaking at approximately 3.4 ng/mL by week 30 in the mare’s circulation, then steadily
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decrease [10]. Though concentrations are low in maternal circulation, Ousey et al.,
demonstrated the uptake of P5 into uteroplacental tissue from the fetus by measuring
blood flow and P5 concentrations to and from the fetus and placenta via the umbilical
artery and vein [4]. Results indicated concentrations of approximately 5-10 μmol/min
flowing from the fetus to the uteroplacental tissue, while less than 1 μmol/min of P5
entered maternal circulation from the uteroplacental tissue, with concentrations rising
throughout gestation. This uptake from the utero-placental tissue, with low output into
the mare’s circulation, suggests P5 is metabolized in the placenta and serves as a
precursor for downstream pregnanes.
While the majority of P5 is directed to the placenta for metabolism (Figure 2.1) [3], fetal
P5 metabolism results in pregnanes such as 3β-hydroxy-5α-pregnan-20-one (3β5P), 5pregnene-3β,20β-diol (P5ββ), and 5a-pregnane-3β,20β-diol (ββ-diol) [30]. In vitro work
showed that the fetal liver possesses the ability to metabolize P5 to P5ββ and ββ-diol by
the enzyme 20β-reductase [30]. Further work by Schutzer and Holtan also showed
conversion of P5 to P5ββ and ββ-diol in the fetal liver with tissue incubations, as well as
conversion of 3β5P to ββ-diol [24].

These pregnanes are preferentially directed to the

uteroplacental tissue, although they are also present in the mare’s circulation [4], with
maternal concentrations of 3β5P, P5ββ, and ββ-diol reaching 100 ng/mL, 10 ng/mL, and
100 ng/mL, respectively, in late gestation (326-350 days) [11]. The fetus is also capable
of converting placental metabolites, delivered to the fetus by the umbilical vein; 5αdihydroprogesterone (DHP) is the progestogen which enters fetal circulation in the
largest quantities, while P4 has also been shown to do the same but in smaller
concentrations [4].
5

Of the metabolites of P5, P4 is the hormone most commonly associated with pregnancy.
However, the mare possesses a number of progestogens and pregnanes which allow the
continuation of pregnancy in late gestation in the absence of circulating P4. Schutzer
demonstrated evidence of this when he inhibited 3β-hydroxysteroid-dehydrogenase (3βHSD) in pregnant mares in mid-gestation. Three β-hydroxysteroid-dehydrogenase is a
placental enzyme necessary for the conversion of P5 to P4 in the placenta. Inhibition of
3β-HSD increased P5 and the fetal metabolites (3β5P, P5ββ, and ββ-diol), with a
decrease in P4 metabolites (P4 was unmeasurable in this study). Inhibition of 3β-HSD
did not result in abortion with the presumed decrease in P4 production, leading to the
presumption that other pregnanes must be bioactive in mid to late gestation in the place
of P4 [16].
Progesterone itself begins to decline rather early in gestation.

The peak of P4

concentrations can be seen by approximately 12 weeks of gestation with peak
concentrations of approximately 11 ng/mL [10]. Progesterone begins to decline to
concentrations of ≤1 ng/mL [2, 3, 10] throughout late gestation. In early pregnancy, P4 is
essential to maintain myometrial relaxation [1, 31-33] by reducing the number of gap
junctions and receptors for oxytocin and prostaglandin F2α. Though circulating P4 can
be below detectible levels in late gestation, this is not to say it ceases to be produced.
Production of P4 continues throughout gestation; however, it becomes a major substrate
for other pregnanes which are metabolized in the placental tissue, and is therefore not
easily detected in the maternal circulation [4].
Perhaps the most notable metabolite of P4 is DHP. This progestogen is converted by the
enzyme 5α-reductase, primarily found in the placenta and endometrium of the mare [12,
6

23]. This progestogen increases from approximately 1.5 ng/mL in the early weeks of
pregnancy and peaks at approximately 37 ng/mL shortly before parturition [10]. It
parallels P4 concentrations by less than half, then surpasses P4 concentrations by
approximately fifteen weeks of gestation [10, 12]. Fifteen weeks is also the time that
marks the luteo-placental shift, in which the primary site of P4 production ceases to be
the corpus luteum, and placental metabolism takes over [10]. Until relatively recently,
there was only speculation that DHP was a bioactive progestogen [10, 12].

However,

work by Scholtz et al., showed that DHP is not only a quantitatively important P4
metabolite, but also sufficient for the maintenance of pregnancy in the absence of P4
[12].

DHP binds the progesterone receptor (PR) with similar affinity as P4 [13],

suggesting that DHP could function in late gestation to maintain myometrial relaxation.
Administration of DHP to a group of early pregnant mares which had undergone
luteolysis via administration of PGF2α demonstrated that DHP alone could maintain
pregnancy with seven of the nine mares with pregnancy maintenance without P4. This
work was central to understanding how equine pregnancy can be maintained in late
gestation when P4 concentrations are often undetectable.
Other bioactive progestogens include allopregnanolone and potentially 20α-hydroxy-5αpregnan-3-one

(20α5P)

and

5α-pregnane-3β,20α-diol

(βα-diol)

[9,

14,

15].

Allopregnanolone, a direct DHP metabolite converted by the enzyme 3α-hydroxysteroid
dehydrogenase (3αHSD) [14] is neuroactive, having the capability of crossing the bloodbrain barrier and allosterically binding GABAA receptors [14, 29]. This elicits a calming
response on the central nervous system and is considered a protective hormone [34].
Allopregnanolone suppression has been linked to cell death in the brain as well as
7

delayed myelination of white matter, [28] indicating its importance to brain development.
Further, allopregnanolone is credited for suppressing the activation of the hypothalamicpituitary-axis (HPA) of the dam and reducing fetal exposure to maternal glucocorticoids
[35, 36]. In an in-vivo study by Madigan et al., allopregnanolone infusion in a healthy
foal resulted in behavioral suppression [15]. This gives evidence of the possible role
allopregnanolone plays in fetal quiescence during mid-to late gestation, when
concentrations rise. Allopregnanolone concentrations rise from approximately 1 ng/mL
in week nine of gestation, to approximately 20 ng/mL near parturition [10].
In vitro work has demonstrated the possible bioactivity of 20α5P and βα-diol [9].
Identified by Holtan in 1991 [3], these metabolites of DHP both reach concentrations
greater than 200 ng/mL in late gestation. They were found to be able to bind PRs using a
luciferase reporter assay [9], although they did so at less than half the affinity of P4.
Potential exists for these metabolites to elicit a response in later gestation; however, they
are not considered key players in pregnancy maintenance. Concentrations mirror DHP,
increasing by 15 weeks to approximately 300 ng/mL for 20α5P and approximately 480
ng/mL for βα-diol by week 50 [10].
Other quantitatively important pregnanes include 20α-hydroxyprogesterone (20αOH-P4),
20β-hydroxyprogesterone (20βOH-P4), and 17α-hydroxyprogesterone [10, 11, 18]. With
the exception of 17α-hydroxyprogesterone, which is a necessary metabolite leading to the
production of cortisol [37, 38]; little is known about the function of these pregnanes in
the mare. These P4 metabolites are synthesized in the placenta and available in maternal
circulation. Concentrations for these pregnanes vary in the times in which they peak,
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with 17α-hydroxyprogesterone peaking in week 8 of gestation [10], while 20αOH-P4
and 20βOH-P4 are not detectible until after 300 days of gestation [11].
Parturition in the mare is marked, in part, by a distinct and reliable rise and decline in
circulating pregnanes, along with production of fetal cortisol [3, 9, 23, 39, 40]. This
pattern is linked to the activity of the fetal adrenal, the gland responsible for the
production of P5. It is thought that activation of the hypothalamic-pituitary axis (HPA) is
responsible for the surge in circulating pregnanes found in the mare’s circulation [18].
Previous studies show that administering ACTH to the fetus results in increased
pregnanes in the mare’s circulation before 300 days of gestation. After 300 days, a
progressive shift from P5 production to cortisol production in the fetal adrenal occurs [41,
42]. Approximately 4-5 days before parturition, there is a surge in fetal cortisol [18, 43].
The enzyme necessary for the synthesis of cortisol, P450C17, has been shown to be
present in the fetal adrenal by immunohistochemistry [26].

More importantly,

immunohistochemical staining was very limited in early gestation with increases noted
rapidly prior to parturition. This shows that the fetal adrenal is likely producing cortisol
just prior to parturition, in agreement with the surge of cortisol observed. Thus, with the
shift in production of cortisol, a decrease in pregnanes can be seen.
Pregnanes in late gestation in the compromised pregnancy
Pregnane profiles are frequently used as a diagnostic tool for potentially compromised
pregnancies in late gestation [6, 7, 44]. When taken in account with other clinical signs,
these profiles can provide information regarding the health of the fetus and placenta. As
has been previously discussed, the fetus and placenta work together to produce pregnanes
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found in circulating maternal blood. Therefore, abnormal changes can be attributed to
disturbances to the normal synthetic pathway for these pregnanes.

Typically, these

patterns are a measure of total pregnanes by immunoassay, with three main patterns
common in cases of abnormal pregnancy [5].
The first pattern is identified by a rapid decline in total pregnanes. This pattern is
typically seen with acute dysfunction resulting in fetal demise, such as uterine torsion,
colic, maternal stress, or acute cases of placentitis [45-47]. Another potential cause is the
demise of a single fetus in a twin pregnancy; in this situation, the adjoining area between
the placentas is already avillous [48], and when the placenta supporting the deceased
fetus necrotizes, a substantial loss in pregnane metabolism occurs [49]. As the fetus is
responsible for production of P5, any case in of fetal demise will result in a loss of
precursor and therefore a decline in measurable pregnanes in the mare’s circulation.
The second pattern includes cases where pregnanes are relatively high for the given stage
of gestation. While such elevated concentrations are typically observed just prior to
parturition, chronic cases of placentitis, placental edema, and placentas with poorly
developed or sparse microvilli can result in this pattern of measured pregnanes [5, 6, 50].
This is believed to be associated with fetal stress which result is an increase in P5
production from the fetal adrenal, ultimately leading to an increase in total pregnanes [27,
41]. Though foals born to mares which display this pattern are often born prematurely,
they tend to fair better than those born prematurely to mares which did not display this
increase. This is thought to be due to the increased activation of the HPA axis [5, 51].
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The third pattern can be observed when the normal prepartum rise in pregnanes fails to
occur. This is most often seen in prolonged gestation caused by ingestion of tall fescue
containing endophyte fungus [5]. Fescue toxicosis is thought to inhibit fetal cortisolreleasing hormone (CRH) by the ergot alkaloids present in the fescue, therefore inhibiting
the normal function of the adrenal gland to produce the cortisol surge and associated
changes in pregnane metabolism [8].
Mass spectrometry, either LC-MS/MS or GC/MS, have been used to better understand
specific changes related to abnormal pregnancies that would not be discernable with
immunoassay. Utilizing GC-MS, Ousey et al., reported changes in ten specific pregnanes
(P5, P4, 3β5P, P5ββ, ββ-diol, βα-diol, DHP, 20α5P, 20α-hydroxyprogesterone, and 20βhydroxy progesterone) from healthy mares compared to a set of mares with clinical issues
or placental abnormalities. Mares with pregnancy complications were grouped based
upon diagnosis; placentitis, placental pathology without placentitis, and non-placental
problems. Results for the placentitis group showed increases in all measured pregnanes,
including P4 and P5. This suggested an increase in precursors due to fetal stress and
increased metabolites as a result.

For the group with placental pathology but no

placentitis, (including placental edema and avillous placenta), an increase in total
pregnanes was noted with P4, specifically, also increased.

Most of the individual

pregnanes measured, however, were either in a normal range or decreased. As this group
had issues with the placenta, it appears as though the placental function was affected and
its ability to metabolize pregnanes was reduced. For the group of mares with problems
unrelated to the placenta, (including colic, uterine rupture, uterine torsion, laminitis foot
surgery, and a mare with premature mammary development) the majority had a decrease
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in total pregnanes.

These mares also showed a decrease in most of the individual

pregnanes. These fetuses were significantly compromised or dead, therefore precursor
was reduced, or non-existent, with downstream metabolites reduced as well [11]. This
study, coupled with the diagnosis, was useful to understand how differential issues with a
pregnancy could present as different pregnane profiles. Further work and use of GC-MS
or LC-MS/MS in the future may prove beneficial in predicting pregnancy outcome in
cases of suspected pregnancy compromise. However, this technology is expensive and
requires a skillset beyond that required of immunoassays and will unlikely be used
regularly by clinics in the near future.
Attempts to better understand the pathogenesis of diseases and to better understand the
function of certain pregnanes, related to feto-placental metabolism have ranged from
inducing disease to inhibiting key enzymes. The most studied disease related to the
placenta is ascending placentitis, as this represents the major cause of pregnancy loss or
complication in late gestation [44, 52]. Ascending placentitis can be experimentally
induced by removing the cervical mucus plug and introducing bacteria into the cervix [6,
53].

One of the most common causes of ascending placentitis is the bacteria

Streptococcus equi subspecies zooepidemicus [54], and this bacteria is commonly used in
cases of experimentally induced placentitis.

The infection establishes itself at the

cervical star and ascends down the placenta, causing inflammation and placental
separation [52].

By knowing the interval of time from inoculation to abortion,

researchers were able to distinguish between acute and chronic pregnane profiles. Morris
et al., described a pattern of decreasing plasma pregnanes in cases of acute induced
placentitis where the interval from inoculation to abortion was less than seven days;
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conversely, a pattern of increasing pregnanes was observed in chronic cases (>7 days)
[6]. Canisso et al., also described this pattern in unpublished reports from experimentally
induced placentitis [55].
Enzyme inhibition studies have also been useful to better understand necessary pathways
in equine pregnancy.

Work to inhibit 3β-HSD, the enzyme responsible for the

conversion of P5 to P4, gave evidence that other progestogen or progestogens may be
responsible for pregnancy maintenance in late gestation besides P4. Fowden et al.,
attempted to inhibit the action of 3β-HSD with epostane, a competitive 3β-HSD inhibitor.
Late pregnant mares (292-330 days gestation) received epostane, which resulted in a
decrease in plasma progesterone concentrations by immunoassay, but no effects on
gestation length [43]. Schutzer et al., conducted a similar study utilizing trilostane,
another 3β-HSD inhibitor, during late gestation (277-282 days gestation). In this study,
GC-MS was used to measure specific pregnanes. While P4 was undetectable during the
study, an increase in P5, ββ-diol, and 3β5P was noted in maternal plasma; while DHP,
20α5P, and βα-diol were decreased. Further, trilostane inhibited the conversion of P5 to
P4 while increasing DHP and 3β5P concentrations when placental tissue was exposed to
labeled P5 or P4. Again, there was no effect of 3β-HSD inhibition on gestation length
[16]. Both studies demonstrated the ability of mares to maintain pregnancies in the face
of apparent decreases in P4 and its metabolites, as well as emphasizing the unique
hormone metabolizing ability of the feto-placental unit. In a third study, Chavatte et al.,
demonstrated the natural inhibition of 3β-HSD activity caused by pregnanes close to term
with an in vitro study using placentas from pregnancies spanning 250-320 days of
gestation [21]. These results suggest the possibility of the prepartum rise in pregnanes to
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inhibit 3β-HSD, thereby affecting pregnane concentrations as they relate to the onset of
parturition. These studies, focusing on 3β-HSD activity, demonstrated the importance of
the enzyme for pregnane metabolism in the pregnant mare, but were unable to
significantly affect gestational outcome. This suggests the importance of other enzymes
present during this time of gestation which work together to maintain pregnancy.
Schutzer’s work also focused on pregnane synthesis during gestation, and resulted in a
proposed alternate pathway for metabolism of DHP beyond the 5α-reduction of P4.
Incubation of labeled P5 showed conversion of P5 to 3β5P in endometrial tissue while
labeled 3β5P was converted to DHP in placental tissue incubations. Further, infusion of
P5 and 3β5P in a pregnant mare both resulted in elevated concentrations of DHP [24].
This suggested the possibility of 5α-reduction of P5 to 3β5P and then 3-oxidation to
DHP. However, recent work disputes this pathway by demonstrating an inability of 5αreductase to metabolize P5 [56]. Taken together, these studies highlight the complexity
of pregnane metabolism in the mare.
As DHP has been found to be an important progestogen in late gestation, a study
attempting to inhibit the enzyme responsible for its metabolism, 5α-reductase, was
conducted. Utilizing the 5α-reductase inhibitor finasteride, Ousey et al., administered the
inhibitor to mares beginning at 300 days of gestation with the objective of inhibiting the
enzyme and monitoring changes to timing of parturition and changes in pregnane
profiles. Results indicated that the treated mares had significantly shorter gestation
lengths than the control mares. Further, total pregnanes by immunoassay were elevated
in the peripheral circulation of treated mares and P4 was increased as measured by GCMS; however, no change was seen in DHP or other measured pregnanes [57]. This study
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demonstrated the possible effects of finasteride in vivo by shortening gestation and
altering P4 concentrations. This study also suggested the importance of 5α-reductase in
late gestation.
While studies to induce disease and inhibit steroidogenic enzymes have helped us learn
more about the pathways and how disease can affect pregnane metabolism, there is still a
significant amount of work needed to fully understand the biosynthesis of pregnanes by
the equine feto-placental unit.
Methods of detection
Assays have been used to identify and quantify hormones for many years. Despite early
difficulties, breakthroughs in sensitivity, specificity, automation, and commercialization
have allowed hormone detection to become easier and more accessible [9-11, 17, 58, 59].
Radioimmunoassays (RIA), developed in the sixties [60] allowed the researcher to detect
hormones with greater sensitivity and specificity and with greater ease than previous
methods. Prior to RIAs, quantification of hormones was a laborious process which
required large amounts of sample [61] and were not highly specific [62].
Radioimmunoassays depend on antibodies raised to an antigen of interest and on
radioactive signal from a radioisotope, typically iodine-125, which is attached to the
antigen of interest and competes for the binding site of the antibody used. A gamma
counter then detects the amount of free radiolabeled antigen in the supernatant after
incubation with a sample; serum for example. During the early stages of RIAs, nonspecificity was a common problem. This was due, in large part, to lack of standardization
of reference preparations. Standardization and development of more specific antibodies
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improved agreement [63]. While this offered researchers an easier and more reliable
form of detection, it came with its own set of issues. This technology required specific
equipment and proper disposal of radioactive material. This assay method is still used
today, though many labs have stopped using it, in favor of other assay methods.
Non-isotopic immunoassays are common in many clinics and labs, having taken the place
of RIAs for hormone detection with no need for special disposal. Like RIAs, this assay
method relies on the development of the antibody used to capture the antigen of interest.
Detection is achieved with color intensity using enzyme linked immunosorbent assays
(ELISA) [11], intensity of light with electrochemiluminescence (ECL) [59], or intensity
of fluorescence with enzyme linked fluorescence assays (ELFA) [64] . Multiple methods
for detection using the antibodies include: indirect, direct, sandwich, competitive, or
some combination of methods to optimally capture the antigen of interest [65].
Measuring pregnanes in the late pregnant mare has been mostly dependent on P4
immunoassays for their ease of use and cost effectiveness.

Though P4 is low to

undetectable in late gestation, these assays rely on the ability of the progesterone
antibody to cross-react with pregnanes that are present in the mare’s blood during this
time [7, 11]. There are a number of P4 antibodies available, and their ability to crossreact with other pregnanes varies.
Polyclonal antibodies (PABs) tend to cross-react to a higher degree than monoclonal
antibodies which target a single epitope. An antigen, P4 in this case, is injected into an
animal and the animal’s immune system produces antibodies to the foreign P4 [63, 66].
The animal, typically a rabbit, is then bled by exsanguination; however, a larger animal
may be used if a large volume of antibody is required. These antibodies tend to be less
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specific as antibodies to all epitopes of the antigen will have been produced and will be
present in the blood [67]. Purification and separation of antibodies can be accomplished
using columns to help eliminate unwanted antibodies [68]. An advantage of PABs is
they take less time to develop, (4-8 weeks) [66] and can use the cross-reactivity to benefit
measurements of total pregnanes when certain pregnanes (P4) are in such low
concentrations [69].

The obvious disadvantage is they tend to have higher cross-

reactions and antibodies will differ from lot to lot.
Monoclonal antibody (MAB) production is more intensive and takes much longer to
produce that PABs (3-6 months) [66], but yields a more specific antibody. In 1975,
Köhler and Milstein published research that would earn them a Nobel Prize by fusing two
cells which could ultimately produce an antibody that could be reproduced from that
same line of fused cells [70]. Like PAB development, an animal is injected with the
antigen of interest. These antibodies are typically developed in mice and the spleen is
harvested, as opposed to blood collection [66]. Antibody-secreting B cells are taken and
fused with myeloma cells to produce hybridoma cells. These cells take advantage of the
proliferation of cancer cells to be able to produce (clone) unlimited amounts of the same
antibody [63, 67]. Further, as individual cells are separated, selection for antibody
specificity is possible [67]. These antibodies have the advantage of higher specificity,
though MABs may be produced with high cross-reactivity [71], and the ability to produce
unlimited amounts of a single antibody lot. Polyclonal and monoclonal antibodies can
cross-react to differing degrees, and while this can be advantageous when analyzing total
pregnanes, it has potential to cause confusion due to the variations in results.

17

The comparisons of immunoassay results from lab to lab, or clinic to clinic, can cause
discrepancies in interpretation when two or more different antibodies or assays are used
to measure target hormones [72, 73]. Further, antibodies used in research are not as
regulated as antibodies used in human clinical medicine [74]. For this reason, a reference
range of normal values and thresholds for an assay should be established for a given time
in gestation when samples would typically be analyzed [75], and interpretations should
consider the cross-reactivities of the antibody used. It is also helpful to analyze serial
samples from a mare in question, as variations in profiles can be seen even in healthy
pregnancies [76], and single samples have not been shown to be diagnostic [47].
Immunoassays have become increasingly commercialized and sample results are
available within the same day [58, 59]. Assays have come a long way since the use of
bioassays, but an even more reliable method of detection for individual pregnanes can be
found in mass spectrometry. Immunoassays will likely continue to dominate as the
method of choice due to ease of use and cost. However, GC-MS and LC-MS/MS have
become the gold standard for analyte detection.
Unlike immunoassays which depend on the quality and development of the antibody
used, GC-MS and LC-MS/MS rely on the mass to charge ratio (mass/charge) of the
analyte of interest. Pregnanes are quite similar in structure [65] and therefore cross-react
easily with antibodies, but they differ in their mass/charge, and this is the basis for
detection with mass spectrometry. Short and Holtan demonstrated that P4 was actually
low to undetectable in mid to late gestation [2, 3]. Prior to this finding, immunoassays
displayed an increase in what was thought to be P4, but what was actually the total
pregnanes able to cross-react with the antibody.
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Mass spectrometry requires specialized equipment and expertise to analyze the results
and is therefore expensive for typical use in diagnosis with pregnancy complications.
However, its use in research has been important to understand changes in pregnanes
throughout pregnancy as well as in cases of pregnancy complications [3, 9-12]. Mass
spectrometry takes advantage of the separation abilities of chromatography and the mass
detection of the individual analyte with the mass spectrometer. Whether GC-MS or LCMS/MS is used, some basic similarities exist for detection and measurement. A purified
sample of analyte is needed for method development and serves as a standard reference.
Method development includes selection of the mobile phase, selection of the stationary
phase, temperature and pressure settings, and analysis of peaks generated from a detector.
The selection of the mobile phase and stationary phase takes into consideration the
analyte to be measured, possible interactions with the mobile phase (selected gas or
solvent), and the affinity for the analyte in the column [77].
Mass spectrometry, along with gas or liquid chromatography, is beneficial as some
analytes will have similar retention times (amount of time it takes for the analyte to elute
from the column), and therefore simple chromatography wouldn’t be adequate for analyte
identification. As the analyte enters the mass spectrometer, it encounters an ionization
source and the analyte is ionized. The mass of the analyte after ionization will be noted
and a mass range is selected. Selection considers mass observed as well as analyte
properties and possible solvent interactions, and all masses outside of that range will be
ignored.

Once the analyte is ionized, it travels in a vacuum through the mass

spectrometer and encounters magnetic or electric fields, typically, which will deflect the
particles not of interest based on the mass range.
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In the case of tandem mass

spectrometry, such as LC-MS/MS, a collision cell then fragments the original analyte to
daughter ions which can help to further differentiate analytes which are very similar in
mass or structure [65]. Detectors at the end of the spectrometer transforms detected ions
to interpretable results displayed as peaks of mass to charge ratios. Once the reference
standard has been identified, samples can be analyzed and compared to the standard.
Like other assay methods, a standard curve is generated to allow the quantification of the
analyte in the sample. In addition to the ability to distinguish between similar analytes,
GC-MS and LC-MS/MS allow for detection and quantification of multiple analytes
within the same sample [9-11], saving time and sample volume.
The complexity of pregnane metabolism and the changes observed through gestation and
in cases of pregnancy issues in the late pregnant mare have been brought to light through
the use of GC-MS and LC-MS/MS. Though GC-MS and LC-MS/MS have increased
detection specificity and sensitivity, as they can detect concentrations down to 0.1 ng/mL
[10], they aren’t as affordable or easy to use as immunoassays. Much has been learned
through their use, but immunoassays will likely continue to dominate as the method of
choice for diagnosis with pregnancy issues in the mare. Reference ranges for individual
immunoassays and cross-reactivities with the antibody should always be considered, as
well as the time in gestation of the mare, to interpret assay results.
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Figure 2.1 Pregnane metabolism in the pregnant mare
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Abstract
In the latter half of gestation in the mare, progesterone (P4) concentrations decline to near
undetectable

levels

while

other

pregnanes

are

elevated.

Of

these,

5α-

dihydroprogesterone (DHP) and allopregnanolone have been reported to have important
roles in either pregnancy maintenance or fetal quiescence. During this time, the placenta
is necessary for pregnane metabolism, with the enzyme 5α-reductase being required for
the conversion of P4 to DHP. The objectives of this study were to assess the effects of a
5α-reductase inhibitor, dutasteride, on pregnane metabolism (pregnenolone (P5), P4,
DHP, 20α-hydroxy-5α-pregnan-3-one (20α5P), 5α-pregnane-3β,20α-diol (βα-diol), and
allopregnanolone), to determine circulating dutasteride concentrations, and to assess
effects of dutasteride treatment on gestational parameters. Pregnant mares (n=5) received
dutasteride (0.01 mg/kg/day, IM), and control mares (n=4) received vehicle alone from
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300 to 320 days of gestation or until parturition. Concentrations of dutasteride, P5, P4,
DHP, 20α5P, βα-diol, and allopregnanolone were evaluated via liquid chromatography
tandem mass spectrometry (LC-MS/MS). Samples were analyzed as both days post
treatment and as days prepartum, using a random effects mixed model with time,
treatment, and time by treatment as fixed effects and mare as random effect. Gestational
data and neonatal outcome were analyzed with a Wilcoxon signed-rank test.

No

significant treatment effects were detected in P5, DHP, 20α5P, βα-diol, or
allopregnanolone for either analysis; however, P4 concentrations were increased (p<0.05)
in dutasteride-treated mares compared to control mares.

Dutasteride concentrations

increased in the treated mares, with a significant correlation (p<0.05) between dutasteride
concentrations and P5 or P4 concentrations. Gestational length and neonatal outcomes
were not significantly altered in dutasteride-treated mares; however, placentas from
treated mares were significantly heavier (p<0.05) than the placentas from control mares.
Results from this study suggest the ability of dutasteride to inhibit pregnane metabolism
as P4 concentrations were altered. Although 5α-reduced metabolites were unchanged,
these data suggest an accumulation of P4 precursor with inhibition of 5α-reductase.
Keywords: 5α-reductase, pregnanes, mare, LC-MS/MS
Introduction
Progesterone (P4) is the primary hormone for pregnancy maintenance in most
mammalian species [1]. Acting through the progesterone receptor (PR), P4 maintains
myometrial quiescence and prevents premature parturition [1, 78]. In contrast to other
species, the mare has little detectable P4 in peripheral blood after mid-gestation [2-4, 12].
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Although P4 levels rise dramatically during early pregnancy, analysis via mass
spectrometry indicates that P4 concentrations begin to decline around 80 days of
gestation and are undetectable by day 200 [10, 12]. Several pregnanes are present in high
concentrations at this time, including 5α-dihydroprogesterone (DHP), 20α-hydroxy-5αpregnan-3-one (20α5P), 5α-pregnane-3β,20α-diol (βα-diol), and allopregnanolone [4, 9,
10, 30] (Table 3.1). Specifically, DHP is a direct metabolite of P4 and is known to bind
the PR and maintain pregnancy in the absence of P4 [1, 12, 13]. It is believed DHP acts
through the PR to block myometrial activity, thereby maintaining pregnancy [30, 79].
The key enzyme responsible for the conversion of P4 to DHP is 5α-reductase (Figure
3.1). Of the two isoforms known to be present in the mare, 5α-reductase type 1 is the
predominant isoform in the endometrium and chorioallantois [12]. Once 5α-reductase
has metabolized P4 to DHP, DHP can be further metabolized into other pregnanes
including allopregnanolone. This hormone is a neuroactive steroid capable of binding
GABAA receptors to enhance inhibitory neurotransmission [80] and is believed to have a
sedative-like effect on the fetus [15].

In humans, horses, and sheep, peripheral

concentrations of allopregnanolone increase in both the maternal and fetal circulation,
with levels peaking near term [9, 10, 81, 82]. Other DHP metabolites include 20α5P and
βα-diol. The formation of these pregnanes is dependent upon enzyme metabolism within
the uteroplacental tissue, and relative concentrations increase dramatically in mid to late
gestation, similar to DHP [10]. These pregnanes are of interest as they have been shown
to bind PR in vitro [9], and they rely on P4 and DHP as steroidogenic precursors.
To demonstrate the importance of 5α-reductase on pregnane metabolism and pregnancy
health, we evaluated the effects of dutasteride, a type-1 5α-reductase inhibitor.
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Specifically, pregnane metabolism was monitored by measuring concentrations of
specific pregnanes, and pregnancy outcome was evaluated in mares. The hypothesis of
this study was that administration of dutasteride to late pregnant mares would result in a
decrease in DHP, 20α5P, βα-diol, and allopregnanolone.

With a decrease in these

bioactive pregnanes, we further hypothesized a reduced gestational length from mares
administered dutasteride when compared to control mares. The objectives for the current
study were to assess changes in target pregnanes (P4, P5, DHP, 20α5P, βα-diol, and
allopregnanolone) and neonatal outcome in pregnant mares treated with dutasteride
compared to controls.

Concentrations of dutasteride in the maternal and neonatal

circulation, neonatal and placental weight, and neonatal viability were also determined.
Materials and Methods
Animal husbandry
Nine healthy pregnant mares with a mean age of 9.7 yr. (± 1.2 yr.) were used in this
study. Mares were maintained at the Maine Chance Farm, Department of Veterinary
Science, University of Kentucky, Lexington, KY, and all experimental protocols were
approved by the Institutional Animal Use and Care committee at the University of
Kentucky (Protocol #2012-1067). Gestational age was determined relative to day of
ovulation (Day 0). Pregnant mares were maintained on pasture and supplemented with
grain and water, hay, salt, and trace minerals ad libitum. When parturition was suspected
via determination of milk pH [83], mares were moved to individual box stalls for the
night to monitor parturition.
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Study design
Pregnant mares were randomly assigned to treatment (n=5) or (n=4) control groups.
Beginning on day 298 of gestation, jugular venous blood samples were taken daily in 10mL heparinized tubes and 10-mL plain tubes (Becton, Dickinson and Company, Franklin
Lakes, NJ), and blood sampling continued through two days postpartum. Blood samples
were centrifuged at 1,811 × g for ten minutes, and plasma and serum were stored at -20
°C until analysis. Beginning at day 300 of gestation, treated mares received dutasteride
(Aurum Pharmaceuticals; Franklin Park, NJ) at 0.01mg/kg body weight, IM, in an
ethanol/mygliol (Fisher Scientific, Hampton, NH; Warner Graham Company,
Cockeysville, MD) vehicle (60:40, ethanol: mygliol), and control mares received vehicle
alone. Dutasteride or vehicle control administration continued daily until day 320 of
gestation, or until parturition.

Upon mammary development, milk samples were

monitored for pH, to assess impending parturition. When milk pH neared 7.0, a FOAL
ALERT sensor (Foalalert. Inc., Acworth, GA) was sutured to the vulva, per
manufacturer’s instructions. Immediately after parturition, blood was collected from the
neonate and mare via jugular venipuncture. After foaling, weights of the neonate, mare,
and placenta were recorded.
Hormone analysis
Plasma concentrations of P5, P4, DHP, 20α5P, βα-diol, and allopregnanolone were
determined via liquid chromatography-tandem mass spectrometry (LC/MS-MS).
Samples were analyzed every other day beginning at day 298 of gestation and then daily
for nine days prior to parturition. Pregnane concentrations were determined as previously
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reported with an accuracy > 90%, precision < 15%, and average limit of quantification of
0.33 ng/mL [10].
Determination of circulating dutasteride concentrations
Dutasteride concentrations were analyzed at the University of Kentucky Environmental
Research Training Laboratory, utilizing a modified protocol [84]. In short, dutasteride
was measured from serum with a Varian 410 auto sampler, Varian ProStar 210 pumps,
and a Varian 1200L triple quadrupole mass spectrometer (Walnut Creek, CA). This
method utilized a Kinetex C18 column (100 x 2.1 mm x 2.6 µm) (Torrance, CA), with
mobile phase A consisting of water with 0.1% formic acid and mobile phase B consisting
of methanol with 0.1% formic acid. Elution gradient (Table 3.2) and the reporting limit,
quality controls (QC), ions, extraction efficiency, accuracy, and precision (Table 3.3)
were determined. The internal standard, dutasteride-13C6 (Clearsynth; Mississauga, ON,
Canada), was dissolved in methanol at 1mg/mL and diluted to a working concentration of
100 ng/mL. Standards were made by dissolving dutasteride (Aurum Pharmaceuticals;
Franklin Park, NJ) in methanol at 1 mg/mL to give an initial concentration of 100,000
ng/mL. Dilutions were made to produce stock standards at 10,000, 1,000, 100, and 10
ng/mL. Charcoal stripped gelding serum was used for the standard curve points, QCs,
and blanks. Seven standard points at 80, 50, 25, 10, 5, 0.5, and 0.1 ng/mL were used to
generate the standard curve which had an r2 value of .99. Quality controls were assessed
at 35, 15, and 1ng/mL, and triplicates were included of each for the two-batch assays.
Each sample, QC, and standard point was analyzed utilizing 1.0 mL of serum.
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Statistical analysis
Analysis of endocrine data was conducted using two models. The first model examined
endocrine changes between treated and control mares from Day 298 to 318. This model
excluded two mares (one control and one dutasteride-treated mare) as they foaled prior to
318 days of gestation, and the biological decline of pregnanes in the three days prior to
parturition would have confounded the results [10]. In the second model, endocrine data
were analyzed for the nine days prior to parturition with all mares included in the
analysis. Endocrine data were analyzed with a random effects mixed model with mare as
a random effect and time, treatment, and time-by-treatment interactions as fixed effects.
Data were transformed (square root or log transformation) as required and model validity
was tested by examination of normal quantile plots of residuals.

Gestational data

(duration of gestation, neonatal, and placental weights) were analyzed with a Wilcoxon
signed-rank test. Dutasteride concentrations were analyzed with regression plots, of drug
and individual pregnane concentrations. Analysis was conducted utilizing JMP software
(JMP®, Version 12. SAS Institute Inc., Cary, NC), and significance was set at p<0.05.
Data are expressed as mean ± SEM unless otherwise stated.
Results
Foaling outcome
All mares in the study delivered viable foals; however, one of the foals from a control
mare had a severe omphalophlebitis and a patent urachus and was humanely euthanized
at 5 days of age.

Gestational lengths, neonatal weight, and neonatal weight as a

proportion of mare weight were not different between dutasteride-treated and control
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mares (Table 3.4). Two of the dutasteride-treated mares retained their placenta beyond
three hours postpartum. No control mares retained their placenta. Placental weights
were greater in dutasteride-treated mares than in control mares (Table 3.4).
Peripheral pregnane concentrations
For the period between 298 to 318 days of gestation, pregnane concentrations were
evaluated in alternate day samples. For P4, there was a significant effect of time and a
time by treatment interaction, and P4 was higher in dutasteride-treated mares at Days
314, 316 and 318 of gestation (Figure 3.2b). An effect of time was seen for P5, 20α5P,
and βα-diol, but there were no time, treatment or time by treatment effects on
concentrations of DHP or allopregnanolone between Days 298-318 (Figure 3.2). For the
nine days preceding parturition, there was a significant time effect on P5, DHP, 20α5P,
βα-diol, and allopregnanolone with each of these pregnanes decreasing in the three days
preceding parturition (Figure 3.3). For P4, there were significant effects of time and a
time by treatment interaction such that P4 was greater in dutasteride-treated mares at
Days -7, -6, -5, -4, -3 and -2 prior to parturition (Figure 3.3b). Neonate pregnane
concentrations were not different between foals from dutasteride-treated or control mares
(Table 3.5).
Dutasteride in circulation
To assess circulating dutasteride concentrations, samples from treated mares were
analyzed every four days, beginning from day 298 and continuing through parturition
(Figure 3.4), along with a single sample from each of the treated foals to determine if
dutasteride could cross the placenta. Two samples were selected at random from each
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control mare to include in the analysis. Overall, a time-dependent increase of dutasteride
continued for the duration of the treatment. Two mares which foaled after administration
of the final treatment exhibited a continual increase in dutasteride concentrations beyond
D320. No dutasteride was detected in the control mares. In dutasteride-treated mares,
there was a positive correlation between dutasteride concentrations and concentrations of
P5 and P4; however, there was no significant correlation between dutasteride
concentrations and either DHP or allopregnanolone (Figure 3.5).

Dutasteride

concentrations were 22.7 ± 6.7 ng/mL for the single sample taken from the foals of
treated mares at birth.
Discussion
Administration of the 5α-reductase inhibitor, dutasteride, to mares in late gestation did
not alter peripheral concentrations of DHP or its downstream metabolites (20α5P, βαdiol, and allopregnanolone).

However, administration of dutasteride did increase

peripheral concentrations of the precursor, P4, in treated mares. Although metabolism of
pregnanes was altered with the administration of dutasteride during late gestation, there
was no effect of dutasteride administration on the length of gestation or neonatal
outcomes.
In the mare, a normal prepartum rise in circulating pregnanes occurs approximately 30
days before parturition, followed by a rapid decline in the days or hours prior to foaling
[9, 10]. In the current study, changes in measured pregnanes in control and treated mares
appeared similar to those previously reported [9, 10] with the exception of P4 which
increased in mares treated with dutasteride. Ousey et al., reported that administration of
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the 5α-reductase inhibitor, finasteride, beginning at D300 of gestation also increased
concentrations of P4 without decreasing concentrations of DHP [57]. In contrast to the
observations in the current study, Ousey et al., also reported a reduced gestation length in
mares treated with finasteride.
Dutasteride is reported to be 100 times as potent at inhibiting the type 1 isoform of 5αreductase compared to finasteride in humans [85], therefore dutasteride was expected to
have a greater effect in this study when compared to Ousey’s study. Based upon in vitro
observations using equine epididymis as the source of 5α-reductase type 1, both
dutasteride and finasteride inhibit the type 1 isoform of this enzyme with equal potency
and show a resultant block of conversion of P4 to DHP [56]. This is in contrast to
potency differences reported in humans analyzing the enzyme’s ability to inhibit
testosterone conversion [85]. A limitation of the current study is that animal numbers
were small, which may have resulted in our inability to detect treatment effects on
gestation length. Further, it is unknown what concentration or duration of administration
of dutasteride would be required to elicit significant effects on gestation in the mare.
After intramuscular administration of dutasteride, concentrations of the inhibitor rose
slowly and continued to rise in mares after cessation of administration at D320. No data
on half-life of dutasteride in the horse is available, but in humans the cited half-life is
approximately 5 weeks [86]. Peak concentrations of dutasteride in serum of mares were
approximately 86 ng/mL (0.16 μM), well below the published IC50 of dutasteride for
equine 5α-reductase activity (1.0 μM) [56]. The slow release of dutasteride from the
mygliol vehicle and the low serum concentrations of dutasteride achieved during the
treatment period may account for the observed lack of effect of dutasteride on DHP
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concentrations in treated mares. Another possible explanation involves the proposed
alternate pathway to DHP via oxidation of 3β-hydroxy-5α-pregnan-20-one (3β5P) [24].
However, recent work has refuted this pathway [56], and this explanation remains
speculative.
Though dutasteride is typically prescribed for the inhibition of testosterone conversion to
5α-dihydrotestosterone in humans [85], dutasteride significantly reduced conversion of
P4 to DHP in both mice (in vivo) and humans (in vitro) [87, 88]. In human breast tissue,
dutasteride resulted in not only a reduction of 5α-reductase activity, but also a significant
increase in expression of the enzymes 3α-hydroxysteroid oxidoreductase (3αHSOR) and
20α-hydroxysteroid oxidoreductase (20αHSOR) [88], which are two enzymes necessary
for metabolism of DHP to allopregnanolone and 20α5P (Figure 3.1). This suggests
dutasteride would decrease the levels of DHP and other downstream metabolites in
treated mares, and also potentially increase 20α5P, βα-diol, and allopregnanolone
concentrations.

However, in the current study, concentrations of these 5α-reduced

pregnanes remained unchanged after administration of dutasteride. There was, however,
a significant increase in P4 in dutasteride-treated mares that was likely due to a buildup
of substrate when the enzyme was inhibited. The significant correlation observed in
dutasteride and P5 or P4 concentrations further suggests a buildup of substrate with
inhibition. Supporting data for this includes the ability of dutasteride to significantly
increase testosterone concentration in treated men when compared to the placebo group
[89, 90] when inhibiting 5α-reductase in men with benign prostatic hyperplasia.
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Conclusions
Based upon the increase in P4 noted in dutasteride-treated mares during late gestation,
dutasteride did inhibit 5α-reductase activity in mares. Although precursor (P4) increased,
there were no changes detected in 5α-reduced pregnanes (DHP, 20α5P, βα-diol or
allopregnanolone). Results suggest that while a higher dose may have had a greater
affect, a possible alternate metabolic pathway may yet be involved in the complex steroid
metabolism during late gestation in the mare.
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Abbreviation
P5

P4
DHP
20αDHP (a)
3β,20αDHP (a)

Chemical name

Trivial name

pregn-5-ene-3β-ol,20-one (a)
3β-hydroxy-5α-pregnen-20-one (b)
3β-hydroxy-5-pregnen-20-one (c,d)
pregn-4-ene-3,20-dione (a)
4-pregnene-3,20-dione (b,c,d)
5α-pregnan-3,20-dione
5α-pregnan-20α-ol-3one (a)
20α-hydroxy-5α-pregnan-3-one (b,c,d)
5α-pregnan-3β,20α-diol (a)
5α-pregnane-3β,20α-diol (b,c,d)

pregnenolone

Alternative
abbreviation

progesterone
(5α)dihydroprogesterone
20α-hydroxy DHP (a)
3β,20α-dihydroxy DHP (a)

5αDHP
20α5P (b,c)
20α5α (d)
βα-diol (b,c,d)
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Table 3.1: Pregnanes referenced in this paper along with a comparison of pregnane identifications among published articles.
a) Legacki et al., [10] b) Ousey et al., [11] c) Chavatte et al., [21] d) Schutzer et al., [24]

Time

%A

%B

Flow

0:00

50

50

0.2

0:30

50

50

0.2

7:00

5

95

0.2

9:00

5

95

0.2

10:00

50

50

0.2

18:00

50

50

0.2
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Table 3.2 Elution gradient, with mobile phase A consisting of water with 0.1% formic acid, and B consisting of methanol with
0.1% formic acid. Flow rate was 0.2 mL/min.

Compound

Rt

Precursor
Ion

Daughter
Ions

Reporting
Limit

Dutasteride

7.8

529

461, 264, 187

Dutasteride 13C6

7.8

535

467, 270, 187

QCH
%CV/%Acc

QCM
%CV/%Acc

QCL
%CV/%Acc

%EE

0.1

4.8/97.8

5.9/97.6

4/109.7

83.6

0.1

NA

NA

NA

86.7
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Table 3.3 Compounds listed with retention time (Rt) in minutes, precursor ions, daughter ions,
reporting limit, precision (%CV) and accuracy (%Acc) of quality controls (QCH, QCM, and QCL), and extraction efficiency
(%EE). Daughter ions are listed in order of abundance, with the ion of quantification bolded. Reporting limit is listed in ng/mL
and was determined by the lowest standard visible with a linear curve. Precision and accuracy for QCH, QCM, and QCL were
determined by two runs containing triplicates of each QC. Percent accuracy was assessed by dividing the average QC values by
the actual values and multiplying by 100. Extraction efficiency was calculated by dividing the area of the peak with extraction for
dutasteride by the area of the peak without extraction for dutasteride and multiplied by 100.

Group

Gestation length
(days)

Neonatal weight
(kg)

Neonatal/mare weight
(%)

Placental weight
(kg)

Dutasteride

323 (318, 335)

51 (42, 55)

0.085 (0.073, 0.090)

4.7 (4.5, 5)*

Control

337 (321, 352)

40 (37, 62)

0.071 (0.062, 0.086)

3.1 (2.3, 3.8)*

Table 3.4 Gestational length and neonatal outcome. Data represent the median with the 25th and 75th quartile indicated in
parenthesis. Asterisks indicate significant differences between groups (p<0.05)

Dutasteride

Neonatal
Pregnenolone
725.5 (±140.2)

Neonatal
Progesterone
3.3 (±0.6)

Neonatal
DHP
21.8 (±2.4)

Neonatal
Allopregnanolone
3.8 (±1.4)

Neonatal
Dutasteride
22.7 (±6.7)

Control

834.0 (±308.6)

2.5 (±0.7)

24.6 (±8.7)

4.0 (±1.9)

0

Group

Table 3.5 Concentrations of pregnane and dutasteride concentrations (ng/mL) in neonatal foals born to dutasteride-treated and
control mares. No significant differences were observed between groups. Data are mean ± s.e.m.

37

Figure 3.1 Pregnane metabolism in the pregnant mare
Fetus

Placenta
3βHSD

P5

Mare

P4

P4
5α-reductase

3β5P

3-oxidase

DHP

DHP

3β-oxidoreductase
20αHSOR

20α5P
DHP

3βHSOR

βα-diol

3αHSOR
20β-reductase

ββ-diol

20α5P

Allopregnanolone
ββ-diol

βα-diol
Allopregnanolone
ββ-diol

Pregnenolone (P5), progesterone (P4), 5α-dihydroprogesterone (DHP), 3β-hydroxy-5αpregnan-20-one (3β5P), 20α-hydroxy-5α-pregnan-3-one (20α5P), 5α-pregnane-3β,20αdiol (βα-diol), and allopregnanolone. Enzymes include 5α-reductase, 3β-oxioreductase, 3oxidase, 3β-hydroxysteroid dehydrogenase (3βHSD), 3α-hydroxysteroidoxidoreductase
(3αHSOR),
20α-hydroxysteroidoxidoreductase
(20αHSOR),
and
3βhydroxysteroidoxidoreductase (3βHSOR). Adapted from Ousey et al., 2003 [4].
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Figure 3.2 Plasma pregnane concentrations in control mares (dashed line) and
dutasteride-treated mares (solid line) from 298 – 318 days of gestation.
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All graphs show days of gestation on the x-axis, with treatment beginning on day 300.
Data represent ± 1 SEM.
Fig. a) Mean pregnenolone (P5) concentrations. No difference noted between groups.
Fig. b) Mean progesterone (P4) concentrations. Significant differences, indicated with
asterisks (p<0.05), noted between groups on days 314, 316, and 318.
Fig. c) Mean 5α-dihydroprogesterone (DHP) concentrations. No differences noted
between groups.
Fig. d) Mean 20α-hydroxy-5α-pregnan-3-one (20α5P) concentrations. No difference
noted between groups.
Fig. e) Mean 5α-pregnane-3β,20α-diol (βα-diol) concentrations. No differences noted
between groups.
Fig. f) Mean allopregnanolone concentrations. No difference noted between groups.
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Figures 3.3 Plasma pregnane concentrations in control mares (grey) and dutasteridetreated mares (black) for the last nine days of gestation.
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All graphs show days preceding parturition on the x-axis. Data represent ± 1 SEM.
Fig. a) Mean pregnenolone (P5) concentrations. No differences noted between groups.
Fig. b) Mean progesterone (P4) concentrations. Significant differences, indicated with
asterisks (p<0.05), noted between groups for days -7, -6, -5, -4, -3, and -2 preceding
parturition.
Fig. c) Mean 5α-dihydroprogesterone (DHP) concentrations. No differences noted
between groups.
Fig. d) Mean 20α-hydroxy-5α-pregnan-3-one (20α5P) concentrations. No differences
noted between groups.
Fig. e) Mean 5α-pregnane-3β,20α-diol (βα-diol) concentrations. No differences noted
between groups.
Fig. f) Mean allopregnanolone concentrations. No differences noted between groups

Figure 3.4 Dutasteride concentrations in treated mares, showing the increase in
dutasteride concentration during and post treatment. Days of gestation are indicated on
the x-axis with the last day of treatment on day 320, and concentrations of dutasteride are
shown along the y-axis in ng/mL. Individual mare identification is listed above the
graphs. Mares A8 and C4 foaled prior to the end of treatment.
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Figures 3.5 Regression plots for pregnanes and dutasteride concentrations in mares
treated with dutasteride from 298-320 days of gestation.
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For each graph, pregnane concentration is indicated along the y-axis in ng/mL and
dutasteride concentration along the x-axis in ng/mL. Slope, intercept, and coefficient of
determination (R2) can be seen in the upper left corner of each graph.
Fig. a) Pregnenolone (P5) concentrations were significantly (p<0.05) and positively
associated with dutasteride concentrations.
Fig. b) Progesterone (P4) concentrations were significantly (p<0.05) and positively
associated with dutasteride concentrations.
Fig. c) 5α-dihydroprogesterone (DHP) concentrations were not significantly associated
with dutasteride concentrations.
Fig. d) Allopregnanolone concentrations were not significantly associated with
dutasteride concentrations.
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Abstract
Endocrine biomarkers, such as pregnanes, are commonly measured to help diagnose
compromised pregnancies in mares in late gestation.

Interpretation of pregnane

concentrations are complicated during late gestation as multiple pregnanes are found in
high concentrations and may variably cross-react in immunoassays.

Therefore,

immunoassay results are assay dependent when attempting to quantify pregnanes in late
gestation. Several pregnanes are thought to be important in late gestation, based on either
their concentration or bioactivity, but cannot be specifically measured by immunoassay.
For this reason, quantification of progesterone and other pregnanes has been conducted
with gas chromatography mass spectrometry (GC-MS) or liquid chromatography tandem
mass spectrometry (LC-MS/MS) in order to better identify changes in pregnanes of
interest. This study’s objective was to measure via LC-MS/MS specific pregnanes in
mares with experimentally induced ascending placentitis (n = 7) and to observe changes
in these target hormones when compared to a group of gestationally age matched control
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mares (n = 8). Target analytes were measured for days -8, -6, -4, -3, -2, -1, and 0 days
preceding abortion in the treated mares, and for the matched days of gestation for the
control mares by LC-MS/MS and by immunoassay.

Measured analytes included

pregnenolone (P5), progesterone (P4), 5α-dihydroprogesterone (DHP), allopregnanolone,
3β-hydroxy-5α-pregnan-20-one (3β5P), 20α-hydroxy-5α-pregnan-3-one (20α5P), 5αpregnan-3β,20α-diol (βα-diol), and 5α-pregnan-3β,20β-diol (ββ-diol). Data was analyzed
with a random effects mixed model with time, treatment, and time × treatment interaction
as fixed effects and mare as random effect. For total pregnanes by immunoassay and P4,
20α5P, and βα-diol by LC-MS/MS, a significant effect (p<0.05) of time, treatment, and
time × treatment interaction was detected. A time and time × treatment interaction was
observed for DHP, allopregnanolone, and 3β5P, but no significant effects were detected
for P5 or ββ-diol. Inoculated mares demonstrated a significant increase in measured
pregnanes when compared to the control mares. This premature rise in pregnanes in the
inoculated mares mirrors that of the normal change in pregnanes seen in healthy
pregnancies just prior to parturition.
Keywords: equine, pregnancy, LC-MS/MS, pregnanes, placentitis
Introduction
The endocrine profile of pregnanes in the mare in late gestation is complex and unique.
Unlike many other mammals [1], progesterone (P4) concentrations in pregnant mares
decline around mid-gestation and remain low or undetectable (<1 ng/mL) [2, 3, 10, 12]
throughout late gestation until the time of parturition, when a slight rise in P4
concentrations has been identified [1, 10]. As P4 is considered critical for pregnancy
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maintenance, these low concentrations of P4 in mid to late gestation represent a
somewhat unusual aspect of reproductive biology in the horse. However, the mare is
known to produce a number of other pregnanes and progestogens during this time which
may be bioactive and thereby serve important functions in pregnancy maintenance [10,
12].
The metabolism of these pregnanes is complex, requiring contributions from the fetus,
placenta and endometrium of the pregnant mare [4, 16] (Figure 4.1). Several pregnanes
have gained attention for their abundance or possible bioactivity in late gestation. These
include: 5α-dihydroprogesterone (DHP), allopregnanolone, 3β-hydroxy-5α-pregnan-20one (3β5P), 20α-hydroxy-5α-pregnan-3-one (20α5P), 5α-pregnane-3β,20α-diol (βα-diol),
and 5α-pregnane-3β,20β-diol (ββ-diol) [3, 10]. Of these, 20α5P and βα-diol are the most
quantitatively important, reaching concentrations of >300ng/mL in late gestation [3, 11].
Others, (DHP, 3β5P, and ββ-diol), have been shown to increase to concentrations of >30
ng/mL during late gestation [4, 10]. While the bioactivity of certain pregnanes have been
evaluated in-vivo [9, 12], the bioactivity of many pregnanes in the mare remains
unknown, despite their high concentrations in late gestation [3, 9, 10]. Of the pregnanes
evaluated for possible bioactivity, P5, P4, DHP, and allopregnanolone are considered
important for their bioactive role or as necessary precursors for bioactive progestogens
[4, 12, 14, 15].
The role of P4 during pregnancy is well documented, having the ability to bind
progesterone receptors (PR), maintain myometrial relaxation, and serve as a precursor for
further metabolites [1, 4, 10]. Progesterone is a metabolite of pregnenolone (P5) which
may originate from the fetal adrenal cortex [4], and possibly the fetal gonads [24, 28],
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and P5 is metabolized in the placental tissue by 3β-hydroxysteroid-dehydrogenase
(3βHSD; Figure 4.1) [91]. Progesterone is then converted to DHP via 5α-reductase in the
placenta [4]. 5α-dihydroprogesterone can be metabolized to other hormones or serve its
proposed function in binding PRs and maintaining myometrial quiescence [4, 12, 24].
Allopregnanolone is an important metabolite of DHP and a potent neurosteroid, known
for binding GABAA receptors [80]. Allopregnanolone helps maintain fetal sleep and fetal
quiescence in utero [14, 15].
Immunoassays, specifically P4 immunoassays, have been traditionally used to evaluate
changes in pregnane concentrations which could be indicative of diseased states or
abnormal pregnancy in mares.

Chronic disease involving the placenta, such as

placentitis, show a gradual increase in pregnanes, while acute disease, such as fetal
demise, result in an abrupt decline in pregnanes [5, 6, 50]. Attempts to study pregnane
concentrations as a predictive tool have been reported with pregnane measurements by
immunoassay prior to 308 days of gestation, indicating placental dysfunction in mares
with differing chronicity of placentitis [50]. Because these observations were made in
mares with spontaneous clinical placentitis, gestational ages, sample number, causative
organism, and pregnancy outcomes varied.
Unlike immunoassays, which report all pregnanes able to cross-react with the antibody,
analysis by mass spectrometry is able to report concentrations of specific pregnanes in
late gestation. Ousey et al., used gas chromatography mass spectrometry (GC-MS) to
describe notable changes in profiles of specific pregnanes in mares with abnormal
pregnancies compared to a group of mares with healthy pregnancies. Within the cases
reported, mares with placentitis had serum concentrations of 20α5P, βα-diol, and ββ-diol
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which were markedly increased when compared to the control mares (above 99.8%
confidence limits). Concentrations of DHP and 3β5P increased, but to different degrees
with different causes of placentitis (placentitis, fungal placentitis, focal placentitis).
Changes in P5 ranged from highly decreased to highly increased among the differing
cases of placentitis [11]. While these changes gave important information about the
measured precursor or specific metabolites and how they related to fetal or placental
function, the samples were generated from clinical cases where gestational ages, sample
number, causative organism, and pregnancy outcomes varied. Therefore, analysis by
mass spectrometry from a controlled study with serial samples from mares with a known
diagnosis may better define target pregnane profiles. The purpose of this study was to
investigate the effects of experimentally induced ascending placentitis on a set of target
pregnanes (P5, P4, DHP, allopregnanolone, 3β5P, 20α5P, βα-diol, and ββ-diol),
measured by LC-MS/MS, compared to gestationally age matched control mares.
Materials and Method
All plasma samples used in this study were generated from previous experiments in
which placentitis was induced via intracervical inoculation of Streptococcus equi spp.
zooepidemicus in mares between 260-280 days of gestation [53, 92]. Samples from
inoculated mares (n = 7) in which the interval from inoculation to abortion was ≥ 8 days
were selected for analysis as a previous report indicated that this interval was associated
with elevations in plasma progestins [50].

Plasma samples from gestationally age

matched mares (n = 8) were used as controls. In inoculated mares, the interval from
inoculation to abortion was 13.4 ± 6.4 days (mean ± sd). Blood samples were drawn
daily via jugular venipuncture into 10-mL heparinized tubes (Becton, Dickinson and
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Company, Franklin Lakes, NJ). Immediately following collection, blood was centrifuged
at 600 × g for ten min. Plasma was then frozen at -20˚C until time of analysis. Samples
were analyzed for days -8, -6, -4, -3, -2,

-1, and 0 days preceding abortion for the

treated mares and for the matched days of gestation for the control mares.
LC-MS/MS
Standards and solutions
Standards for the hormones (Table 4.1.) examined in this study were purchased from
Steraloids (Newport, RI, USA): P5, P4, DHP, allopregnanolone, 3β5P, 20α5P, βα-diol,
ββ-diol, and d9-P4.

A master stock solution of each analyte in methanol (Fisher

Scientific, Hampton, NH) at an initial concentration of 100,000 ng/mL was used to
produce working solutions at concentrations of 10,000, 1,000, 100, and 10 ng/mL. An
internal standard of d9-P4 (IS) at an initial concentration of 100,000 ng/mL in methanol
was diluted to a working concentration of 100 ng/mL.
Sample preparation and extraction
One milliliter of serum was added to a 13x100 mm glass screw-top tube and 100 μL of
working IS was added and briefly vortexed. Standard curve points (ranging from 0.011000 ng/mL) and quality control samples (high (QCH): 300 ng/mL, and low (QCL): 30
ng/mL) were simultaneously prepared by the addition of 100 μL of working IS and the
corresponding volume of working solutions to one milliliter of charcoal stripped gelding
serum and briefly vortexed. Five milliliters of diethyl ether, (Fisher Scientific, Hampton,
NH) was added to each sample and mixed for 15 min on a rotating rack. Samples were
centrifuged at 3000 x g for five minutes. Tubes were held in liquid nitrogen for 45 sec,
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until the serum was frozen, and the supernatant was decanted into a 12x75 mm glass
tube. Samples were dried under a steady stream of nitrogen gas using a drying rack
(Pierce Reacti-Therm Heating Module) until ~0.5 mL remained, at which time a glass
pipette was used to rinse the sides of the tube with 0.5 mL diethyl ether, and the samples
were allowed to dry completely under nitrogen gas. Samples were reconstituted with 150
μL of methanol and vortexed for 15 sec. Standard curve points were generated at the
beginning of each assay, with a repeat analysis of the 100 ng/mL standard at the end of
the assay to assess possible assay drift. Quality control samples were included in every
assay. The IS was selected based on its close resemblance to the analytes of interest.
LC-MS/MS analysis
LC-MS/MS analysis of samples was achieved with the use of a Varian 410 auto sampler,
Varian ProStar 210 pumps, and a Varian 1200L triple quadrupole mass spectrometer
(Walnut Creek, CA) with argon as the collision gas. This method utilized a C18 column
(100 x 2.1 mm x 2.6 µm) (Kinetex; Torrance, CA), with mobile phase A consisting of
water with 0.1% formic acid and mobile phase B consisting of methanol with 0.1%
formic acid. An elution gradient for this method can be seen in Table 4.2. Injection
volume was 25 μL with a flow rate of 0.20 mL per minute. Ionization was achieved with
an atmospheric-pressure chemical ionization (APCI) box in positive mode. Extraction
efficiency was assessed by comparing recovery peaks of each analyte at equal amounts of
working solution from non-extracted and extracted samples. Efficiencies were found to
be >87% for each analyte, with an average of 92%. Accuracy was found by dividing the
QC results from seven runs by the predicted value and multiplying by 100. Average
accuracy was 98.1%. Precision was evaluated with coefficients of variation (CV) using
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the QCs across seven assays, with an average CV of 9.4%. The reporting limit for each
analyte was found by assessing the lowest linear standard point on the curve which could
be clearly identified. Extraction efficiencies, details of analyte identification, and QC
data can be seen in Table 4.3.
Sample preparation, extraction, and analysis by immunoassay
Sample analysis by immunoassay was conducted with P4 antibody R4859 (Clinical
Endocrinology Laboratory, University of California, Davis, CA) utilizing a modified
protocol [93]. Ten microliters of serum was mixed with 0.5 mL of petroleum ether
(Fisher Scientific, Hampton, NH) in a glass tube and vortexed for 45 seconds. Serum
was frozen by holding the tube in liquid nitrogen, and the ether was decanted into a clean
glass tube and dried overnight under a fume hood. Samples were reconstituted with 100
µL of phosphate buffered saline with 0.1% bovine serum albumen (Sigma, St. Louis,
MO) and HRP conjugated with P4 (Clinical Endocrinology Laboratory, University of
California, Davis, CA) at 1:45,000.
Steraloids (Newport, RI).

Progesterone standard was purchased from

Progesterone dissolved in methanol (Fisher Scientific,

Hampton, NH) was used to generate a standard curve with nine standard points, ranging
from 2.5 - 2500 ng/mL. Standard points were made by pipetting appropriate amounts of
solution into glass tubes and allowing to dry, then reconstituting with 2 mL of HRPconjugated buffer.
For the standard plate and separate sample plates, 50 µL of HRP-conjugated buffer was
pipetted across a 96-well plate, previously coated with antibody. The standard curve was
generated by adding 50 µL of each standard in replicates of eight across the plate.
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Curves were linear with correlation coefficients of >0.99. Samples were pipetted on
separate plates in duplicate at 50 µL. High (300 ng/mL) and low (9ng/mL) controls were
included in duplicate on each plate. After two hours of incubation, the plate was washed
three times and substrate (2,2'-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid)
(ABTS) in citric acid (Sigma, St. Louis, MO)) was pipetted across the plate at 100
µL/well. After a second incubation of 1.5 hours, 100 µL of stop solution (EDTA in
hydrofluoric acid (Sigma, St. Louis, MO)) was added to each well and the plates were
read with an Epoch microplate spectrometer (BioTek, Winooski, VT). All samples were
analyzed in a single assay with an intra-assay CV of 8.4%.
Statistical analysis
Pregnane concentrations were analyzed with a random effects mixed model with mare as
a random effect and time, treatment, and time × treatment interactions as fixed effects.
Data were log transformed, and model validity was assessed by examination of normal
quantile plots of residuals for the mixed model. For P4 and P5, censored data (below the
LOD of the assay) were substituted using LOD/sqrt 2 as the estimate for values below
LOD [94]. Pairwise comparisons were made using preplanned comparisons in the testslice function of JMP. Analysis was conducted utilizing JMP software (JMP®, Version
12. SAS Institute Inc., Cary, NC, 1989-2007.), and significance was set at p<0.05. Data
are expressed as the mean ± SEM.
Results
There were significant time, treatment, and time × treatment interactions for P4, 20α5P,
and βα-diol by LC-MS/MS, and total pregnanes by immunoassay. Likewise, there were
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significant time and time × treatment interactions for DHP, allopregnanolone and 3β5P.
There were no significant time, treatment or time × treatment interactions for P5 or ββdiol. Significant increases in target pregnanes (excluding P5 or ββ-diol) were detected in
the eight days leading to abortion in the mares with experimental placentitis when
compared to the matched controls (Figure 4.2).

In contrast, there were no significant

changes in measured pregnane concentrations over the eight days sampled in control
mares.
Discussion
To the authors’ knowledge, this is the first report to examine changes in maternal
concentrations of pregnanes measured by LC-MS/MS in a controlled study of mares with
experimentally induced ascending placentitis. Control mares with normal pregnancies
maintained concentrations of target and total pregnanes comparable to results previously
established for their gestational age, and these concentrations did not vary significantly
during the period under study [9, 10].

Changes in the pregnanes measured in the

inoculated mares were as expected for the disease state, which affects the function of the
placenta and presumably the fetal adrenal gland [5].

This study demonstrated that

profiles of pregnanes in mares with experimentally induced ascending placentitis mirror
those of normal pregnancies, just prior to parturition.
In healthy mares, pregnane profiles have been well established utilizing immunoassays
[3, 7], with variations expected with the P4 antibody used. However, research utilizing
LC-MS/MS or GC-MS has allowed the measurement of individual pregnanes in late
gestation, which would not be possible with immunoassays. Control mares from this
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study ranged in gestational age from 260-280 days, and displayed total pregnane profiles
by immunoassay typical for the given time in gestation. Target pregnanes measured in
the control mares by LC-MS/MS in this study are similar to those previously reported by
LC-MS/MS or GC-MS [4, 9, 10].
In contrast to normal pregnant mares, total pregnanes determined by immunoassay were
significantly elevated in the eight days preceding abortion in mares with experimentally
induced ascending placentitis. This is consistent with reports of elevated pregnanes by
immunoassay in cases of chronic placentitis, defined by an interval of 8 or more days
from inoculation to abortion in experimental cases [6]. Profiles of specific pregnanes by
mass spectrometry in mares with late pregnancy complications have not been well
defined.

However, the inoculated mares in this study had significantly higher

concentrations of most of the target pregnanes. Maximum fold changes were highest for
20α5P (4.6x) and βα-diol (3.6x), with 3β5P, allopregnanolone, and DHP each increasing
approximately two-fold. Concentrations of P4 were also significantly increased with a
maximum fold change of 3.2 after adjusting for concentrations below the LOD, although
P4 concentrations remained relatively low (<2 ng/ml) even in mares with placentitis.
Concentrations of P5 and ββ-diol did not demonstrate significant changes in mares with
placentitis.
Of the target pregnanes measured by LC-MS/MS in this study, all pregnanes which were
significantly increased in the induced mares are pregnanes metabolized in the uteroplacental tissue. A healthy feto-placental unit metabolizes almost all precursor (P5)
coming from the fetus to produce the pregnanes measurable in the periphery of the late
pregnant mare [4]. Previous reports indicate an increase in pregnane concentrations at
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the end of gestation, just prior to a marked decrease which occurs approximately three
days prior to parturition [9, 10]. The increase is thought to be the result of activation of
the fetal hypothalamic-pituitary-adrenal axis (HPA) axis [18] and the fetal adrenal, not
yet able to produce cortisol [26], is stimulated and produces more P5. Evidence of this
can be seen when maternal pregnanes increase in response to fetal administration of
ACTH [41]. The decrease is thought to occur when the enzyme necessary for cortisol
production, P450C17, is expressed in the fetal adrenal gland [26]. With a shift in synthesis
to cortisol, pregnane concentrations decline.
Similarly, cases of placental compromise or other pregnancy insults can lead to increases
in P5 concentrations, and therefore, elevated concentrations of metabolized pregnanes
[11]. This excess in production of P5 is thought to be a response from the fetus to stress
from the disease [44]. Concentrations of P4, 20α5P, βα-diol, DHP, allopregnanolone,
3β5P, P4 and immunoreactive pregnanes appeared to decline in mares with placentitis in
the two days preceding abortion (Figure 4.2), mirroring what would be seen in a healthy
pregnancy just prior to parturition.
Of the target pregnanes in this study, DHP, 20α5P, and βα-diol are the ones most
commonly discussed in previous reports as they are found in the highest concentrations in
maternal serum during late gestation. The significant increase in concentrations of these
pregnanes with disease was not surprising, as this has been previously observed and
reported [11]. While not commonly discussed in many other studies, 3β5P showed a
significant increase in this study. Ousey et al. reported changes in concentrations of 3β5P
from compromised pregnancies in clinical cases, with differences in changes
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corresponding to the diagnosis [11]. However, this is the first study to report increases in
this pregnane in a controlled experiment of mares with ascending placentitis.
Interestingly, measured concentrations of P5 and ββ-diol, which are directly derived from
the fetus [24, 26], were not different in inoculated mares compared to the control group.
Knowing that P5 is the precursor to the downstream pregnanes measured in this study, it
was curious that P5 was not significantly increased in the inoculated mares, when
placental pregnanes were significantly elevated. It is possible that P5 metabolism was
such that, if excess precursor was generated by the fetal adrenal, it was quickly
metabolized before any excess was available for maternal circulation. 5α-pregnane3β,20β-diol (ββ-diol) is a pregnane thought to be metabolized in the fetal liver from P5 or
a P5 metabolite (DHP or 3β5P) [24]. Despite the possibility of metabolism of ββ-diol via
DHP or 3β5P, a lack of increased P5 may have also resulted in a lack of increase in ββdiol for this study. It may also be possible that a lack of increase in P5 or ββ-diol is
associated with ascending placentitis, specifically. However, further work would be
necessary to confirm this.
A comparison of mass spectrometry results from this study and Ousey’s study show
similarities in dramatic increases in total pregnanes, 20α5P, and βα-diol from mares with
placentitis when compared to a control group [11]. Ousey also reported significant
increases for P4, DHP, and 3β5P, as did the current study. However, Ousey reported
changes from multiple placentitis diagnosis, and the increases in these three pregnanes
were not consistent across the diagnosis. Perhaps the most interesting comparison
between these two studies is the results for P5 and ββ-diol. In contrast to Ousey’s results,
this study found no increase in P5 or ββ-diol.
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The complication in making this

comparison between studies potentially lies in the variations of sampling. Ousey’s study
utilized samples from mares with various diagnoses, times in gestation, and sample
numbers. Additionally, as these were mares in a clinical setting, results may have been
confounded by any treatments the mares were receiving. Conversely, parameters in this
current study were well controlled, and the induced mares received no treatments.
Conclusion
Results from this study demonstrate a significant increase in total pregnanes by
immunoassay as well as pregnanes (determined by LC-MS/MS) that are metabolized in
the placenta (P4, DHP, allopregnanolone, 3β5P, 20α5P, and βα-diol) in mares with
induced ascending placentitis. This study demonstrates that in a controlled experiment,
mares induced with ascending placentitis had a similar pregnane profile preceding
abortion to that of mares with normal pregnancies preceding normal parturition.
However, no significant increase by LC-MS/MS was noted for the two pregnanes coming
directly from the fetus (P5 and ββ-diol).

The similarities noted between pregnane

profiles from induced mares in this study and those of healthy mares just prior to
parturition suggest a common mechanism which leads to these changes.
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Steroid Analyzed

Chemical Name

Abbreviation

CAS#

Pregnenolone

5-Pregnen-3β-ol-20-one

P5

145-13-1

Progesterone

4-Pregnen-3,20-dione

P4

57-83-0

5α-dihydroprogesterone

5α-Pregnan-3,20-dione

DHP

566-65-4

3β-hydroxy-5α-pregnan-20-one

3β5P

516-55-2

20α-hydroxy-5α-pregnan-3-one

20α5P

516-59-6

5α-pregnan-3β,20α-diol

βα-diol

566-56-3

5α-pregnan-3β,20β-diol

ββ-diol

516-53-0

Allopregnanolone

5α-Pregnan-3α-ol-20-one

Deuterated Progesterone

4-Pregnen-3,20-dione-2,2,4,6,6,17α,21,21,21-d9

516-54-1
dp-P4

57-83-0
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Table 4.1 Steroids analyzed with common name (if available), chemical name, common abbreviation used in the text, and CAS
number.

Time

%A

%B

Flow

0:00

50

50

0.2

0:30

50

50

0.2

1:30

40

60

0.2

21:00

15

85

0.2

23:00

15

85

0.2

24:00

50

50

0.2

32:00

50

50

0.2
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Table 4.2 Elution gradient, with mobile phase A consisting of water with 0.1% formic acid, and B consisting of methanol with
0.1% formic acid. Flow rate was 0.2 mL/min.
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11.2

Precursor
ion
299

Daughter
ions
281, 159, 131

Reporting
limit
1

QCH
%CV/%Acc
8.5 / 92.9

QCL
%CV/%Acc
9.1 / 99.1

P4

8.7

315

97, 109, 297

0.5

8.9 / 96.4

10.7 / 104.5

94.6

DHP

11.7

317

281, 189, 241

1

10.9 / 89.2

14.5 / 97.9

92.9

3β5P

12.5

301

283, 189, 135

1

11.6 / 89.7

7.8 / 98.1

93.8

20α5P

11.5

319

283, 161, 175

1

7.9 / 94.6

9.6 / 107.2

88.2

βα-diol

11.3

285

135, 175, 189

2.5

8.2 / 95.3

10.1 / 106.9

92.4

ββ-diol

14.2

285

135, 175, 189

1

8.1 / 93.9

12.5 / 104.3

96.8

Allopregnanolone

14.1

301

283, 189, 135

0.5

10.1 / 92.3

8.2 / 98.6

92.7

d9-P4

8.5

324

100, 113, 306

NA

NA

NA

NA

Compound

Rt

P5

%EE
91.1

Table 4.3 Compounds listed with retention time (Rt) in minutes, precursor ions, daughter ions, reporting limit, precision (%CV)
and accuracy (%Acc) of QCH and QCL, and extraction efficiency (%EE). Daughter ions are listed in order of abundance, with
the ion of quantification bolded. Reporting limit is listed in ng/mL. Precision and accuracy for QCH and QCL were determined
by seven runs, one for each batch of samples. Percent accuracy was assessed by dividing the average QC values by the predicted
values and multiplying by 100. Extraction efficiency was calculated by dividing the area of the peak with extraction for each
analyte by the area of the peak without extraction for each analyte and multiplied by 100.

Figure 4.1 Pathway of hormones of interest, including proposed alternate pathways.
Cholesterol
1

P5
2

P4
7

allopregnanolone

3

3

DHP
4

8

βα-diol

20α5P

5
8

3β5P

Enzymes
1. P450 sidechain cleavage
2. 3β-HSD
3. 5α-reductase
4. 3β-oxidoreductase
5. 3-oxidase
6. 20β-reductase
7. 3αHSOR
8. 20α-reductase
Alternate pathway
(Schutzer et al. 1996)

6

ββ-diol
Hormones of interest: pregnenolone (P5), 4-Pregnen-3,20-dione (P4), 5αdihydroprogesterone (DHP), 3β-hydroxy-5α-pregnan-20-one (3β5P), 5α-pregnan-3β,20βdiol (ββ-diol), allopregnanolone, 20α-hydroxy-5α-pregnan-3-one (20α5P), 5α-pregnan3β,20α-diol (βα-diol). Adapted from Ousey et al., 2004 [95].
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Figure 4.2 Measured pregnanes by LC-MS/MS
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Each graph shows results for treated mares (black) and control mares (grey).
Concentrations in ng/mL are reported along the y-axis for each graph and the days
preceding abortion for the treated mares shown along the x-axis. Control mares were
matched based upon relative days of gestation. Each graph includes error bars
representing ± 1 SEM. a) 20α-hydroxy-5α-pregnan-3-one (20α5P). b) 3β-hydroxy-5αpregnan-20-one (3β5P). c) 5α-pregnan-3β,20α-diol (βα-diol). d) 5α-dihydroprogesterone
(DHP). e) Allopregnanolone. f) Progesterone (P4). g) Progesterone (P4) immunoassay
(total pregnanes). h) 5α-pregnan-3β,20β-diol (ββ-diol). i) Pregnenolone (P5). For all
analysis excluding results for ββ-diol and P5, a significant difference was observed
between groups. Asterisks indicate significant difference between groups (p<0.05).
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Chapter Five: A comparison of progesterone assays for determination of peripheral
pregnane concentrations in the late pregnant mare
Michelle A. Wynn1, Erin L. Legacki2, Alan J. Conley2, Shavahn C. Loux1, Alejandro
Esteller-Vico1, Scott D. Stanley3, Thomas E. Curry, Jr.4, Edward L. Squires1, Matts H.
Troedsson1, Barry A. Ball1
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Gluck Equine Research Center, Department of Veterinary Science and 4Department of

Obstetrics and Gynecology, University of Kentucky, Lexington, KY 40546
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Department of Population Health and Reproduction and 3Department of Molecular

Biosciences, School of Veterinary Medicine, University of California, Davis, CA 95616

Abstract
During the latter half of gestation in mares, there is a complex milieu of pregnanes
detectable in peripheral circulation. Pregnane concentrations are often measured during
late gestation to assess pregnancy well-being by immunoassay. However, interpretation
of these results is complicated by the numerous pregnanes present in high concentrations
during late gestation in the mare and by the cross-reactivity of immunoassays with these
pregnanes.

Further, many mares are supplemented with an exogenous progestin,

altrenogest, which may also cross-react with existing assays.

Therefore, the first

objective of this study was to compare assay results from four immunoassays (mini
VIDAS®, Immulite 1000, and two in-house ELISAs; antibody R4859 and CL425) to P4
and DHP concentrations measured with liquid chromatography tandem mass
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spectrometry (LC-MS/MS). The second objective was to assess the cross-reactivity of
pregnenolone, P4, DHP, allopregnanolone, and altrenogest in these four immunoassays,
as these pregnanes are important in late gestation. Blood samples from four healthy
mares in late gestation were evaluated by immunoassays and LC-MS/MS, with the data
analyzed by regression and Bland-Altman analyses.

Results indicate actual

concentrations of P4 (via LC-MS/MS) correlated best to results by Immulite 1000, while
DHP concentrations correlated best to mini VIDAS® results. Cross-reactivity findings
resulted in no cross-reaction of altrenogest with any immunoassay, but varying degrees of
cross-reactivity with other pregnanes analyzed. Results from Bland-Altman analysis
indicate considerable variations in method results, with all methods significantly different
than the P4 concentrations found with LC-MS/MS.

These data confirm pregnane

determination by immunoassay during late gestation varies depending upon the assay
used and the cross-reactivity to other pregnanes present in late gestation, although the
synthetic progestin altrenogest did not affect the results of any immunoassay tested.
Though high correlation is observed in results from the immunoassays tested and P4 by
LC-MS/MS, each assay reported poor agreement in measurement methods when
compared to LC-MS/MS.
Keywords: Immunoassay, cross-reactivity, pregnanes, LC-MS/MS, equine, pregnancy

Introduction
Maintenance of pregnancy is largely attributed to progesterone (P4); however, other
progestogenic hormones are quantitatively more important in pregnancy maintenance
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during the latter half of gestation in the mare. For the first 80 days of gestation, P4 is
considered the primary progestogen (steroid hormone that is able to bind the progesterone
receptor) and is produced by the primary and secondary corpora lutea [3, 10, 96].
However, a luteo-placental shift occurs in the latter half of gestation, at which time P4
concentrations drop to low or undetectable levels (< 1ng/mL) and the primary site for
pregnane (steroid hormones in the progesterone family, not necessarily bioactive)
production shifts from the ovaries to the feto-placental unit [2-4, 10]. Specifically, the
feto-placental unit initiates production of a number of pregnanes, originating from the
precursor pregnenolone (P5), synthesized by the fetus [4, 23, 24]. These pregnanes are
believed to play a role in maintenance of pregnancy in the latter half of gestation, and are
present in concentrations ranging from 10 to >400 ng/mL [3, 9, 10, 24, 30]. Though the
bioactivity of most of these pregnanes remains unknown, 5α-dihydroprogesterone (DHP)
is bioactive in the mare and is able to bind the equine progesterone receptor with equal
affinity as P4 [12, 13]. Additionally, DHP is able to maintain pregnancy in the absence
of P4 [12]. A derivative of DHP, allopregnanolone, is also active in late gestation.
Working through GABAA receptors, allopregnanolone elicits a suppressive response on
the nervous system [34], and may play a role in maintaining fetal quiescence in late
gestation [15]. While the biological function of other pregnanes is currently unclear, they
are present in high concentrations in late gestation [9, 10, 95] and frequently cross-react
with antibodies used in P4 immunoassays [7].
Determination of progesterone concentrations by immunoassay in late gestation is
commonly carried out to help diagnose issues with the pregnancy such as placentitis [5,
6, 54]. In placentitis, acute disease typically results in a rapid decrease in total pregnanes
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whereas chronic disease is associated with increase in total pregnane concentrations [5,
6].

In both situations, interpretation of peripheral progesterone concentrations is

complicated by the variable cross-reactivity inherent with immunoassays [7], as well as
the high concentrations of pregnanes present in maternal circulation during late gestation
which are structurally similar (Figure 5.1). Further, comparisons of results from lab to
lab can be difficult as assays will report different concentrations, depending upon the
antibody used. Due to these complications, a gold standard in detection has become
liquid chromatography tandem mass spectrometry (LC-MS/MS). The use of LC-MS/MS
has resulted in the ability to specifically identify and quantify individual pregnanes in late
gestation. By being able to measure specific pregnanes, researchers have been better able
to understand how certain pregnancy complications in late gestation can affect the fetoplacental unit, and unique patterns of target pregnanes are associated with certain
pathologies [11]. However, limitations exist due to the high cost and expertise required
for LC-MS/MS analysis. Conversely, immunoassays are far more affordable and more
readily available. Therefore, immunoassays continue to be the preferred method for
pregnane detection in late gestation.
Another potentially confounding variable is the widespread supplementation of pregnant
broodmares with the synthetic progestin, altrenogest. Beyond its typical prophylactic use,
altrenogest is also supplemented in suspected cases of placental dysfunction, such as
placentitis, to counteract the release of PGF2α [97] and to minimize myometrial
contractility. Due to the similarities in structure between altrenogest and pregnanes
(Figure 5.1), the possibility of cross-reaction in immunoassays exists, potentially leading
to confounding results. Currently, the preferred method to specifically measure
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altrenogest concentrations is liquid chromatography-tandem mass spectrometry (LCMS/MS) [98-100].
Differences in results between immunoassays as well as differences in results from mass
spectrometry when compared to immunoassays have been reported [11, 72, 73, 75]. This
demonstrates the difficulty of trying to make comparisons across immunoassays or to
quantify a targeted hormone in late gestation in the mare. The objectives of this study
were: 1) to compare differences in pregnane concentrations determined with four
immunoassays compared to LC-MS/MS and 2) to assess cross-reactivity observed with
the same immunoassays, specifically considering P4, P5, DHP, allopregnanolone, and
altrenogest.
Materials and Methods
Animal husbandry
Four healthy pregnant mares used in this study were maintained at the Maine Chance
Farm, Department of Veterinary Science, University of Kentucky, Lexington, Ky. All
mares were maintained on pasture and supplemented with grain and water, hay, salt, and
trace minerals ad libitum. Experimental protocols were approved by the Institutional
Animal Use and Care committee at the University of Kentucky (Project #2012-1067).
Study design
Beginning on day 298 of gestation (Day 0 = ovulation), jugular venous blood samples
were taken daily (10-mL plain VACUTAINER), with sampling continued through
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parturition. Following collection, blood was allowed to clot, samples were centrifuged at
1,811 × g for ten minutes, and serum was stored at -20oC until analysis.
Hormone Analysis
To allow for consistent sampling intervals, due to variations in gestation length, samples
were analyzed for 17, 13, 9, 5, 3, and 1 day preceding parturition and also for the day of
parturition. Pregnane concentrations were determined by two in-house ELISAs, with P4
antibodies R4859 and CL425 (Clinical Endocrinology Laboratory, University of
California, Davis, CA) and by two commercial, automated immunoassay platforms: miniVIDAS® (mini-VIDAS®; Biomérieux, Boston, MA) and Immulite 1000 (Siemens
Healthcare Diagnostic Products, Ltd., Malvern, PA).

Each assay was performed

according to the manufacturer’s recommended protocol, or as described below. Aliquots
of the same samples were sent to the University of California, Davis and analyzed via
LC-MS/MS following an established protocol [10] (see below) to determine P4 and DHP
concentrations, specifically. Details for each assay can be seen in Table 5.1. Intra- and
inter-assay coefficients of variation (%CVs) for each assay can be seen in Table 5.2.
Analysis by antibodies R4859 and CL425
Ten microliters of serum was mixed with 0.5 mL of petroleum ether (Fisher Scientific,
Hampton, NH) in a glass tube and vortexed for 45 s. Serum was frozen by holding the
tube in liquid nitrogen, and the ether was decanted into a clean glass tube and dried
overnight under a fume hood. Samples were reconstituted with 100 µL of phosphate
buffered saline with 0.1% bovine serum albumin (Sigma, St. Louis, MO) and HRP
conjugated with P4 (Clinical Endocrinology Laboratory, University of California, Davis,
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CA) at 1:45,000. Progesterone standard was purchased from Steraloids (Newport, RI).
Progesterone dissolved in methanol (Fisher Scientific, Hampton, NH) was used to
generate a standard curve with nine standard points, ranging from 2.5 - 2500 ng/mL.
Standard points were made by pipetting appropriate amounts of solution into glass tubes
and allowed to dry, then reconstituted with 2 mL of HRP-conjugated buffer.
For the standard plate and separate sample plates, 50 µL of HRP-conjugated buffer was
pipetted across a 96-well plate, previously coated with antibody. The standard curve was
generated by adding 50 µL of each standard in replicates of eight across the plate.
Curves were linear with correlation coefficients of >0.99. Samples were pipetted on
separate plates in duplicate at 50 µL. High (300 ng/mL) and low (9ng/mL) controls were
included in duplicate on each plate. After two hours of incubation, the plate was washed
three times and substrate (2, 2'-Azino-Bis-3-Ethylbenzothiazoline-6-Sulfonic Acid
(ABTS) in citric acid (Sigma, St. Louis, MO)) was pipetted across the plate at 100
µL/well. After a second incubation of 1.5 hours, 100 µL of stop solution (EDTA in
hydrofluoric acid (Sigma, St. Louis, MO)) was added to each well and the plates were
read with an Epoch microplate spectrometer (BioTek, Winooski, VT).
Analysis by LC–MS/MS
Standards were purchased from Steraloids: DHP, P4, and d9-progesterone. A master mix
of all reference standards was prepared and diluted in methanol (10, 1, 0.1 and 0.01
ng/mL). Methanol and water were of HPLC grade and obtained from Burdick and
Jackson (Muskegon, MI, USA). Formic acid and methyl tert-butyl ether were of ACS
grade and obtained from EMD (Gibbstown, NJ, USA).
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Samples were extracted according to the method developed and described by Legacki et
al., [10]. Inter- and intra-accuracy and precision were assessed at four QC concentrations
(0.6, 1.5, 20, and 80 ng/mL) for P4 and DHP using six replicates. The analytes were
measured with ≤15% deviation from the expected concentrations for the three highest QC
concentrations and %CV of ≤15%. The analytes had a percent accuracy >90% and a
precision <15%. Curves were linear with correlation coefficients of >0.99.
Cross-reactivity: Standards and solutions
Standards were prepared to determine possible cross-reactions across the immunoassays
for a subset of pregnanes present during equine pregnancy. The following steroids were
obtained from Steraloids: P4, DHP, P5, allopregnanolone, and altrenogest. All steroids
were purchased as crystalline powder and were dissolved in methanol at an initial
concentration of 100,000 ng/mL. Phosphate buffered saline with 0.1% bovine serum
albumen served as the matrix for the standards. Control buffer was tested for matrix
effects on each assay prior to any sample analysis, with no effect noted.
Sample preparation and evaluation
Serial dilutions of each steroid were made at concentrations of 50, 20, 10, 2, 1, 0.5, 0.2,
and 0.1 ng/mL by first drying the stock solution in methanol under air, then reconstituting
with buffer. These concentrations constituted the standard curve for each steroid, and
were used in each immunoassay.

Results were transformed using B/B0, with B

representing treatment, and B0 representing the buffer control. Curves were generated
utilizing Gen 5 software (BioTek Instruments, Inc.), with cross-reactions calculated using
the fifty percent binding found for each steroid. (Brown et al., 2003). Specifically, we
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identified the x-value (concentration) where the curve for each pregnane or altrenogest
crossed 50% binding. The value for P4 was then divided by the value for each steroid and
multiplied by 100 to obtain cross-reactivity estimates.
Statistics
To compare assay results, data were analyzed by linear regression analysis using data
from LC-MS/MS as the x-value and the tested immunoassay as the y-value in the
regression. Data were also analyzed using a Bland-Altman plot (pregnane concentration
measured by LC-MS/MS minus concentration by immunoassay vs. pregnane
concentration measured by LC-MS/MS plus concentration measured by immunoassay /
2). Data were analyzed utilizing JMP software (JMP®, Version 12. SAS Institute Inc.,
Cary, NC, 1989-2007.). Significance was set at p<0.05.
Results
Pregnane analysis via LC-MS/MS
All mares in this study had normal pregnancies and delivered live foals with a mean
gestational age of 329 ± 5.2 d. Average P4 and DHP concentrations peaked at three days
prior to parturition with P4 concentrations of 1.8 ng/mL and DHP concentrations of 79.8
ng/mL (Figure 5.2).
Pregnane analysis via immunoassay
Based upon Bland-Altman analysis, all four immunoassays evaluated gave higher (P <
0.0001) measured concentrations of progesterone than did LC-MS/MS (Figure 5.3).
Mean differences between measurements of pregnanes between LC-MS/MS and
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immunoassay methods were lowest for the Immulite 1000 platform and greatest for the
immunoassay based upon monoclonal antibody CL425 (Table 5.3). Similarly, regression
slopes for pregnane concentrations for immunoassays were positive (P<0.001) with the
Immulite 1000 assay having the lowest slope and the immunoassay based upon
monoclonal antibody CL425 having the greatest slope (Table 5.3).

For each

immunoassay, measured pregnane concentrations were moderately to strongly correlated
(P < 0.001) with measured P4 concentrations determined by LC-MS/MS (Table 5.3).
Linear regression analysis for concentrations of DHP measured by LC-MS/MS versus
pregnane concentrations determined by immunoassay revealed significant positive slopes
for all immunoasays and y-intercepts were greater than zero for both the Immulite 1000
and mini VIDAS® (Table 5.3).
Cross-reactivity
Estimates for cross-reactivity (50% binding (B/Bo) of each measured steroid compared to
progesterone) varied across target pregnanes and immunoassay (Table 5.4 and Figure
5.4). In general, reported and measured cross reactivities against DHP for antibodies
R4859 and CL425 appeared much greater than the automated commercial progesterone
assays (mini VIDAS® and Immulite 1000). None of the assays in this study crossreacted with altrenogest.
Discussion
Results from this study demonstrate the complications of using immunoassays in late
gestation in the mare.

While identical samples were analyzed, variations in cross-

reactivity with the antibody used in each assay resulted in large differences in reported
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concentrations. Immunoassay results from each of the four assays tested did show a
positive and linear correlation with P4 and DHP by LC-MS/MS.

However, when

comparing methods, results indicate poor agreement of each immunoassay to P4
concentrations by LC-MS/MS. Each assay cross-reacted with the tested hormones to a
different degree than reported, indicating an additional complication in interpreting assay
result in late gestation. The synthetic progestin, altrenogest, had not been previously
tested for cross-reactions on any of the four assays and reported no cross-reactions in this
study.
High concentrations of circulating pregnanes in late gestation in the mare can create
difficulties in interpretation of immunoassay results due to the various immunoassays
available and the cross-reactions that can occur with the antibodies. Previous work with
mass spectrometry has analyzed healthy and compromised equine pregnancies in late
gestation [9-11], with unique profiles of specific pregnanes observed in clinical diagnosis
from mares with compromised pregnancies [11]. While this method of analysis is the
superior choice, demand has not yet warranted this technology in most labs. Until then,
immunoassays will remain the dominate method of hormone quantification. As this
study has demonstrated, an emphasis should be placed in understanding a particular P4
assay when analyzing blood samples from mares in late gestation. Being familiar with
the reported cross-reactions and the gestational stage when the sample was taken can
greatly assist the clinician in understanding assay results. However, the clinician should
be aware that differential cross-reactions are possible, even if not reported. An additional
complication in comparing reported cross-reactivities of antibodies is the lack of
standardization in nomenclature (Table 5.5).
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Although it is widely believed that monoclonal antibodies are more specific than
polyclonal antibodies, this is still dependent on the individual antibody. Within this
study, we utilized a monoclonal antibody with very high levels of cross-reactivity (P4
antibody CL425), as well as a polyclonal antibody with minimal cross-reactivity
(Immulite 1000) (Tables 5.1 and 5.5). All assays in this study demonstrated a positive,
linear correlation to P4 and DHP concentrations, despite the variations in reported
concentrations. This was expected, as pregnanes in the mare increase with time leading
up to parturition [3, 9-11]. Further, all assays resulted in better correlation to DHP results
than P4. Again, this is expected as P4 concentrations are negligible in late gestation,
while DHP can reach concentrations of approximately 30-100 ng/mL [9, 10].
When considering each assay individually, the cross-reactivities (Table 5.4 and Table
5.5) help to explain the correlation results (Table 5.3). The Immulite 1000 had the
greatest correlation to P4 by LC-MS/MS. The reported cross-reactivities are very low,
and this platform is the most specific for P4 of the immunoassays tested. The study
results indicated no cross-reactivity with the target pregnanes; however, this did not agree
with the reported values.

We speculate that lengthening the curve with additional

standard points at higher concentrations would have resulted in cross-reactions for P5,
DHP, and allopregnanolone (Figure 5.4).
The mini VIDAS® had the best correlation with DHP by LC-MS/MS. Again, when
considering the cross-reactivity rates, this assay is reported to cross-react with DHP but
little else. Study results for cross-reactions indicate possible cross-reactions with DHP
and P5, which was not reported to cross-react, but not to allopregnanolone or altrenogest.
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Similar to the Immulite 1000, it appears as though additional standard points in higher
concentrations would have resulted in a cross-reaction for allopregnanolone (Figure 5.4).
Antibodies R4859 and CL425 exhibited the highest cross-reactivity in terms of number of
pregnanes/hormones and percent of possible cross-reactions (Table 5.4 and 5.5).
Therefore, it is no surprise that they had the poorest correlations of the assays tested with
P4 and DHP concentrations by LC-MS/MS. Results from cross-reactions tested indicate
differential degrees of cross-reactivity, and an additional cross-reaction not previously
reported (allopregnanolone with antibody R4859).

Similar to the previous assays,

altrenogest did not cross-react with either antibody, and in contrast to the pregnanes, it
does not appear that additional standard points in higher concentrations would have
affected the results for any of the assays tested (Figure 5.4). Reported cross-reactions and
tested cross-reactions (besides those for P4) were different in each assay.

Possible

differences in reagents, lab techniques, and human error may explain these variances.
Analysis with Bland-Altman plots were included to showcase the vast differences in
results that can be seen in differing P4 assays during late gestation in the mare. Several
P4 immunoassays are available, but the reported concentrations will be different from
assay to assay, and certainly different from concentrations found using mass
spectrometry. Previous work has shown that while results from different methods may
strongly correlate, poor agreement can exist when comparing methods [101]. In this
study, each P4 immunoassay significantly correlated to P4 concentrations by LC-MS/MS
as discussed previously; however, poor agreement was observed in each immunoassay
when compared to LC-MS/MS as immunoassays report results from all possible crossreactions and actual P4 is negligible at this time in gestation.
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As stated previously, earlier studies have demonstrated variations in immunoassay
results. However, to the author’s knowledge, possible cross-reactions with altrenogest
have not been evaluated with current immunoassays. A previous report showed no crossreaction with altrenogest by radioimmunoassay [102], but this updated analyses may be
useful in cases when a mare is supplemented and the owner or veterinarian may be
concerned with possible cross-reactions. If altrenogest did cross-react with the chosen
immunoassay, it could lead to confusion with the diagnosis or a missed diagnosis.
However, the assays tested in this study indicated that altrenogest did not alter
immunoassay results.
Conclusion
High concentrations of circulating pregnanes in late gestation in the mare create
difficulties in measuring concentrations of specific pregnanes. Adding to this, large
differences between immunoassays are present due to the variable levels of crossreactivity within individual antibodies. Immunoassay results consistently correlated more
strongly with DHP values than P4 in the late pregnant mare, as measured by LC-MS/MS;
however, all immunoassays showed poor agreement to concentrations of P4 by LCMS/MS.

When cross-reactivity levels were analyzed, significant levels of cross-

reactivity were seen with targeted pregnanes, but not with altrenogest. Overall, this study
demonstrates the importance of gaining familiarity with your selected immunoassay
when analyzing pregnane concentrations in the late pregnant mare.
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Immulite 1000
Polyclonal

mini VIDAS®
Monoclonal

R4859
Polyclonal

CL 425
Monoclonal

Sensitivity/Limit
of Detection

0.20 ng/mL

0.25 ng/mL

0.02 ng/mL

0.04 ng/mL

Reportable Range:

0.20-40 ng/mL

0.25-80.0 ng/mL

0.02-200 ng/ml

0.04-200 ng/mL

Antibody Description

Table 5.1 Assay details for each of the immunoassays used. Table indicates the type of antibody used, the sensitivity or limit of
detection, the reportable range, and reported cross-reactivity for each assay.
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R4859

CL425

mini VIDAS®

Immulite 1000

Intra-assay %CV

8.4

11.7

6.3

7.4

Inter-assay %CV

NA

NA

8.2

8

Table 5.2 Average coefficients of variation (%CV) for each assay. Coefficients of variation for immunoassays R4859 and CL425
were calculated by assaying all samples and controls in duplicate. No inter-assay CV was calculated for either of these assays as
all samples were ran in one assay. For the mini VIDAS®, a control and calibration standards are included in each new kit and
assayed prior to samples, with the %CVs reported from the manufacturer. Similarly, the %CVs for the Immulite 1000 are
reported from the manufacturer and high and low controls are assayed in two week intervals.

r

Slope

y-intercept

Bland-Altman
mean
difference

95% CI

CL425
R4859
mini VIDAS®
Immulite 1000
DHP by
LC-MS/MS

0.69
0.68
0.72
0.76

182.6*
73.3*
20.5*
3.4*

59
42.2*
22.1*
2.5*

211.4**
99.8**
38.4**
4.5**

171-297.8
85.4-136.3
35-48.4
4-5.9

CL425
R4859
mini VIDAS®
Immulite 1000

0.88
0.9
0.88
0.86

4.1*
1.7*
0.4*
0.1*

-12.1
11.5
15.3*
1.8*

P4 by
LC-MS/MS
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Table 5.3 Results from regression analysis showing correlation coefficients (r), slopes of the curves, and y-intercepts. Also
showing mean difference by Bland-Altman and 95% confidence intervals (CI) by for each immunoassay platform when
comparing results of P4 or DHP by LC-MS/MS.
*Values for slope and intercept differ from zero (p<0.05).
**Mean difference in Bland-Altman differs from zero (P < 0.01)

R4859

CL425

100

Study
results
%
100

mini VIDAS®
Study
Reported
results
%
%
100
100

Immulite 1000
Study
Reported
results
%
%
100
100

Steroid

Reported
%

Progesterone

100

Study
results
%
100

DHP

12.2

29.3

55

30.6

13

8.6

1

0

P5

0.1

14.5

12.5

18.8

not tested

2.7

0.6

0

Allopregnanolone

0

10.9

64

10

not tested

0

not tested

0

Altrenogest

not tested

0

not tested

0

not tested

0

not tested

0

Reported
%
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Table 5.4 Reported cross-reactivities and cross-reactivities found from this study for each compound, across each assay tested

Immulite 1000
Steroid

mini VIDAS®
%

Steroid

90

Progesterone

100 Progesterone

5β-Dihydroprogesterone
Corticosterone

6.6

20α-Dihydroprogesterone
11-Deoxycorticosterone
Pregnenolone
17α-Hydroxyprogesterone
Testosterone

R4859
%
100

Steroid
Progesterone

CL 425
%
100

Steroid

%

4-Pregnen-3α-ol-3.20188
dione
4-Pregnen-3β-ol-20-one 172
147

1.0

5β17.39 11α-OH-Progesterone 40
dihydroxyprogesterone
5α12.95 5α-Pregnane-3,2012.19 4-Pregnen-11α-ol-3,20dihydroxyprogesterone
dione
dione
17α-hydroxyprogesterone 1.18 17α-OH-Progesterone 0.38 Progesterone

0.8

Deoxycorticosterone

1.15

20α-OH-Progesterone 0.13

94

0.6
0.6

6β-hydroxyprogesterone 0.29
16α-hydroxyprogesterone 0.2

20β-OH-Progesterone 0.13
Pregnenolone
0.12

0.1

Corticosterone

Cortisol

<0.04

20α-hydroxyprogesterone 0.03
Testosterone
0.01

Pregnanediol
Estradiol 17β

<0.01
<0.01

Estrone

0.01

Estrone

<0.01

Estradiol

<0.01 Testosterone

1.9

Table 5.5 Reported cross-reactivities from each assay

0.09

<0.01

5α-Pregnan-3β-ol-20one
Allopregnanolone
5α-Pregnan-3,
20-dione
5β-Pregnan-3b-ol20-one
5β-Pregnan-3,20-dione
4-Pregnen-11β-ol-3,20dione
5β-Pregnan-3α-ol-20one
5α-Pregnan-3α,20β-diol
Pregnanediol
Androstenedione
Corticosterone

100

64
55
12.5
8
2.7
2.5
<0.1
<0.1
<0.1
<0.1

Figure 5.1 Structures of progesterone (P4), pregnenolone (P5), 5α-dihydroprogesterone
DHP), allopregnanolone, and altrenogest.

P5

P4

Allopregnanolone

DHP

Altrenogest
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Figure 5.2 Average pregnane concentrations by four immunoassays and LC-MS/MS

Comparison of Immunoassays to P4 and DHP
1000

CL425
R4859

ng/ml

100

DHP (LCMS/MS)
MiniVIDAS

10

Immulite
1000

1

P4 (LCMS/MS)

0.1
-17

-13

-9

-5

-3

-1

0

Days Prior to Parturition

Average pregnane concentrations (ng/mL) measured in pregnant mare serum (n=4) in
days prior to parturition from antibody CL425 (grey triangles), antibody R4859 (grey
circles), mini VIDAS (grey squares), and the Immulite 1000 (grey diamond).
Concentrations of P4 (black circles) and DHP (black line) measured with LC-MS/MS.
The y-axis was log-transformed to separate the curves. Date represent mean ± S.E.M.
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Figure 5.3 Bland-Altman plots
40
30

60
R4859 ELISA
40

20

20

10

0

0

-2

1 0

50

100
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200

250

300

4

0

100

300

M

500

700

M

10

10 Immulite

VIDAS

50

5

0

0

-5

-5
-1
MS P4

1

10

20

30

40

50

60

0

70

MS-P4

2

4

6

8

10

M

M

Bland Altman plots showing differences in results for each immunoassay compared to
progesterone values found with LC-MS/MS. The difference between a paired set of
measures is plotted on the y-axis, with the mean of the two plotted along the x-axis.
Solid lines indicate mean difference, with dotted lines indicating the upper and lower
95% confidence levels.
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Figure 5.4 Cross reactivity graphs
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94

10

20

50

miniVIDAS
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50
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Cross-reactivity graphs. The y-axis for each graph shows %B/B0 values (defined as
signal from a sample divided by the maximum intensity of signal), and the x-axis is
shown as pregnane concentration (ng/mL). Correlation coefficients (r) are given for each
compound on each assay platform. Cross-reactivities were determined at 50% B/B0.
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Chapter six: Summary and conclusions
Pregnane profiles are complex in the late pregnant mare, as the relationship between the
fetus and placenta is essential in pregnane metabolism. Of the numerous pregnanes that
have been identified, only P4, DHP, allopregnanolone, and potentially 20α5P and βα-diol
have demonstrated bioactivity.

While the function of the remaining pregnanes is

currently not understood, we can speculate that they hold some importance due to their
elevated concentrations at this time in gestation. Measurement of specific pregnanes with
compromised pregnancies has demonstrated significant changes in pregnane profiles.
However, these key changes cannot be detected by immunoassay due to high incidences
of cross-reactions. Future work utilizing LC-MS/MS or GC-MS will allow a better
understanding of changes in pregnanes as they relate to healthy or compromised
pregnancies.
The work in this thesis has demonstrated that attempts to significantly alter pregnancy
outcome by enzyme inhibition is not an easy task. Inhibition of 5α-reductase did not
have a significant effect on gestation length or concentrations of DHP.

It did

significantly increase P4 concentrations in the treated mares, indicating its activity by
producing an increase in a precursor to 5α-reductase.

Although concentrations of

dutasteride were seen to increase even beyond the cessation of treatment, the overall lack
of response suggests that a higher dose or longer treatment period is necessary to elicit a
reliable and significant change in pregnancy outcome or DHP concentrations.
Changes in pregnane concentrations as they relate to pregnancy complications in the
mare have been previously studied. Although immunoassays offer a cost-effective means
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of measurement, the high incidences of cross-reactions make interpretation of assay
results difficult. For this reason, we utilized LC-MS/MS to measure changes in P5, P4,
DHP, allopregnanolone, 20α5P, 3β5P, ββ-diol, and βα-diol, specifically, in a group of
mares with induced ascending placentitis. Concentrations of pregnanes metabolized in
the placenta (P4, DHP, allopregnanolone, 20α5P, 3β5P, and βα-diol) were significantly
increased in the inoculated mares. Changes in pregnane profiles of inoculated mares just
prior to abortion closely mirrored those observed in healthy pregnancies just prior to
parturition, indicating a common mechanism at the end of gestation.
As stated previously, immunoassay results are challenging to interpret in late gestation.
To demonstrate this difficulty, a comparison of four P4 immunoassays was made against
P4 and DHP concentrations by LC-MS/MS. Significant correlations were observed with
all immunoassay results when compared to actual P4 or DHP concentrations, as would be
expected with the natural rise in pregnanes in late gestation.

However, making

comparisons across assays is nearly impossible in late gestation with the variations in
antibodies resulting in significant differences in assay results.
In conclusion, the measurement and interpretation of pregnane concentrations is currently
taking place at a tipping point in technology. Although immunoassays provide a costeffective means of measurement, mass spectrometry is currently the only way to measure
changes in specific pregnanes in late gestation. Alterations to important enzymes through
either naturally occurring disease in pregnancy or in controlled studies will result in
certain changes in pregnanes. These changes, measured by mass spectrometry, will lead
to a better understanding of fetal and placental health and function in late gestation in the
mare, ultimately resulting in improved diagnostic abilities for compromised pregnancies.
97

References
1.
2.
3.
4.

5.
6.

7.

8.
9.
10.
11.

12.

13.

14.
15.

16.
17.

18.

Challis, J.R.G., et al., Endocrine and paracrine regulation of birth at term and
preterm. Endocr Rev, 2000. 21(5): p. 514-50.
Short, R.V., Progesterone in blood. IV. Progesterone in the blood of mares. J
Endocrinol, 1959. 19: p. 207-10.
Holtan, D.W., et al., Plasma progestagens in the mare, fetus and newborn foal. J
Reprod Fertil Suppl, 1991. 44: p. 517-28.
Ousey, J.C., et al., Ontogeny of uteroplacental progestagen production in
pregnant mares during the second half of gestation. Biol Reprod, 2003. 69(2): p.
540-8.
Ousey, J.C., Hormone profiles and treatments in the late pregnant mare. Vet Clin
North Am Equine Pract, 2006. 22(3): p. 727-47.
Morris, S., et al., Transrectal ultrasonography and plasma progestin profiles
identifies feto-placental compromise in mares with experimentally induced
placentitis. Theriogenology, 2007. 67(4): p. 681-91.
Douglas, R.H., Endocrine diagnostics in the broodmare: what you need to know
about progestins and estrogens. Proceedings of the Society for
Theriogenology/American College of Theriogenologists, 2004: p. pp. 106–115.
Cross, D.L., L.M. Redmond, and J.R. Strickland, Equine fescue toxicosis: signs
and solutions. Journal of animal science, 1995. 73(3): p. 899-908.
Legacki, E.L., et al., Progestin withdrawal at parturition in the mare.
Reproduction, 2016. 152(4): p. 323-31.
Legacki, E.L., et al., The dynamic steroid landscape of equine pregnancy mapped
by mass spectrometry. Reproduction, 2016. 151(4): p. 421-30.
Ousey, J.C., et al., Progestagen profiles during the last trimester of gestation in
Thoroughbred mares with normal or compromised pregnancies. Theriogenology,
2005. 63(7): p. 1844-56.
Scholtz, E.L., et al., Pregnancy without progesterone in horses defines a second
endogenous biopotent progesterone receptor agonist, 5alphadihydroprogesterone. Proc Natl Acad Sci U S A, 2014. 111(9): p. 3365-70.
Chavatte-Palmer, P., et al., Progesterone, oestrogen and glucocorticoid receptors
in the uterus and mammary glands of mares from mid- to late gestation. J Reprod
Fertil Suppl, 2000(56): p. 661-72.
Brunton, P.J., J.A. Russell, and J.J. Hirst, Allopregnanolone in the brain:
protecting pregnancy and birth outcomes. Prog Neurobiol, 2014. 113: p. 106-36.
Madigan, J.E., et al., Allopregnanolone infusion induced neurobehavioural
alterations in a neonatal foal: is this a clue to the pathogenesis of neonatal
maladjustment syndrome? Equine Vet J Suppl, 2012(41): p. 109-12.
Schutzer, W.E., J.L. Kerby, and D.W. Holtan, Differential effect of trilostane on
the progestin milieu in the pregnant mare. J Reprod Fertil, 1996. 107(2): p. 241-8.
O'Rorke, A., et al., Development and validation of a monoclonal antibody enzyme
immunoassay for measuring progesterone in saliva. Clinical Chemistry, 1994.
40(3): p. 454-458.
Fowden, A.L., A.J. Forhead, and J.C. Ousey, The Endocrinology of equine
parturition. Exp Clin Endocrinol Diabetes, 2008. 116(7): p. 393-403.
98

19.
20.
21.

22.

23.
24.

25.
26.

27.
28.
29.

30.

31.
32.

33.
34.
35.

36.

Rossdale, P.D. and M. Silver, The concept of readiness for birth. J Reprod Fertil
Suppl, 1982. 32: p. 507-10.
Terblanche, H.M. and L. Maree, Plasma progesterone levels in the mare during
the oestrous cycle and pregnancy. J S Afr Vet Assoc, 1981. 52(3): p. 181-5.
Chavatte, P.M., P.D. Rossdale, and A.D. Tait, Modulation of 3 betahydroxysteroid dehydrogenase (3 beta-HSD) activity in the equine placenta by
pregnenolone and progesterone metabolites. Equine Vet J, 1995. 27(5): p. 342-7.
Krasowski, M.D., et al., Cross-reactivity of steroid hormone immunoassays:
clinical significance and two-dimensional molecular similarity prediction. BMC
Clinical Pathology, 2014. 14(1): p. 33.
Hamon, M., et al., Production of 5 alpha-dihydroprogesterone during late
pregnancy in the mare. J Reprod Fertil Suppl, 1991. 44: p. 529-35.
Schutzer, W.E. and D.W. Holtan, Steroid transformations in pregnant mares:
metabolism of exogenous progestins and unusual metabolic activity in vivo and in
vitro. Steroids, 1996. 61(2): p. 94-9.
Conley, A.J., Review of the reproductive endocrinology of the pregnant and
parturient mare. Theriogenology, 2016. 86(1): p. 355-65.
Han, X., et al., Immunohistochemical localisation of steroidogenic enzymes and
phenylethanolamine-N-methyl-transferase (PNMT) in the adrenal gland of the
fetal and newborn foal. Equine Vet J, 1995. 27(2): p. 140-6.
Ousey, J.C., et al., The effects of intrafetal ACTH administration on the outcome
of pregnancy in the mare. Reprod Fertil Dev, 1998. 10(4): p. 359-67.
MacArthur, E., R.V. Short, and V.J. O'Donnell, Formation of steroids by the
equine foetal testis. J Endocrinol, 1967. 38(3): p. 331-6.
Pashen, R.L. and W.R. Allen, The role of the fetal gonads and placenta in steroid
production, maintenance of pregnancy and parturition in the mare. J Reprod
Fertil Suppl, 1979(27): p. 499-509.
Chavatte, P., et al., Biosynthesis and possible biological roles of progestagens
during equine pregnancy and in the newborn foal. Equine Vet J Suppl, 1997(24):
p. 89-95.
Allen, W.R., Luteal deficiency and embryo mortality in the mare. Reprod Domest
Anim, 2001. 36(3-4): p. 121-31.
Renthal, N.E., K.C. Williams, and C.R. Mendelson, MicroRNAs--mediators of
myometrial contractility during pregnancy and labour. Nat Rev Endocrinol, 2013.
9(7): p. 391-401.
Silver, M., Placental progestagens in the sheep and horse and the changes
leading to parturition. Exp Clin Endocrinol, 1994. 102(3): p. 203-11.
Hirst, J.J., et al., Neuroactive steroids in pregnancy: key regulatory and protective
roles in the foetal brain. J Steroid Biochem Mol Biol, 2014. 139: p. 144-53.
Brunton, P.J., et al., Central opioid inhibition of neuroendocrine stress responses
in pregnancy in the rat is induced by the neurosteroid allopregnanolone. J
Neurosci, 2009. 29(20): p. 6449-60.
Brunton, P.J., et al., Endogenous opioids and attenuated hypothalamic-pituitaryadrenal axis responses to immune challenge in pregnant rats. J Neurosci, 2005.
25(21): p. 5117-26.

99

37.
38.

39.

40.

41.

42.
43.
44.

45.

46.

47.

48.
49.
50.

51.

52.
53.

McKinnon, A.O., Equine Reproduction. Vol. 2nd ed. 2011, Oxford: WileyBlackwell.
Conley, A.J. and A.C. Assis Neto, The ontogeny of fetal adrenal steroidogenesis
as a prerequisite for the initiation of parturition. Exp Clin Endocrinol Diabetes,
2008. 116(7): p. 385-92.
Haluska, G.J. and W.B. Currie, Variation in plasma concentrations of oestradiol17 beta and their relationship to those of progesterone, 13,14-dihydro-15-ketoprostaglandin F-2 alpha and oxytocin across pregnancy and at parturition in
pony mares. J Reprod Fertil, 1988. 84(2): p. 635-46.
Seamans, K.W., et al., Serum levels of progesterone, 5 alphadihydroprogesterone and hydroxy-5 alpha-pregnanones in the prepartum and
postpartum equine. Steroids, 1979. 33(1): p. 55-63.
Rossdale, P.D., et al., Increase in plasma progestagen concentrations in the mare
after foetal injection with CRH, ACTH or betamethasone in late gestation. Equine
Vet J, 1992. 24(5): p. 347-50.
Silver, M. and A.L. Fowden, Prepartum adrenocortical maturation in the fetal
foal: responses to ACTH. J Endocrinol, 1994. 142(3): p. 417-25.
Cudd, T.A., et al., Ontogeny and ultradian rhythms of adrenocorticotropin and
cortisol in the late-gestation fetal horse. J Endocrinol, 1995. 144(2): p. 271-83.
LeBlanc, M.M., M. Macpherson, and P. Sheerin, Ascending placentitis: what we
know about pathophysiology, diagnosis, and treatment. 2004, American
Association of Equine Practitioners (AAEP): Lexington. p. 127-143.
Mizushima, C., Late-term abortion associated with umbilical cord torsion in the
mare: Case report. Journal of Equine Veterinary Science, 2005. 25(4): p. 162163.
van Niekerk, C.H. and J.C. Morgenthal, Fetal loss and the effect of stress on
plasma progestagen levels in pregnant Thoroughbred mares. J Reprod Fertil
Suppl, 1982. 32: p. 453-7.
Santschi, E.M., M.M. LeBlanc, and P.G. Weston, Progestagen, oestrone sulphate
and cortisol concentrations in pregnant mares during medical and surgical
disease. J Reprod Fertil Suppl, 1991. 44: p. 627-34.
Jeffcott, L.B. and K.E. Whitwell, Twinning as a cause of foetal and neonatal loss
in the thoroughbred mare. J Comp Pathol, 1973. 83(1): p. 91-106.
Whitwell, K.E., Investigations into fetal and neonatal losses in the horse. Vet
Clin North Am Large Anim Pract, 1980. 2(2): p. 313-31.
Rossdale, P.D., et al., Effects of placental pathology on maternal plasma
progestagen and mammary secretion calcium concentrations and on neonatal
adrenocortical function in the horse. J Reprod Fertil Suppl, 1991. 44: p. 579-90.
Gravett, M.G., et al., Intrauterine infection and preterm delivery: Evidence for
activation of the fetal hypothalamic-pituitary-adrenal axis. American Journal of
Obstetrics and Gynecology, 2000. 182(6): p. 1404-1413.
Macpherson, M.L., Diagnosis and treatment of equine placentitis. Vet Clin North
Am Equine Pract, 2006. 22(3): p. 763-76.
Canisso, I.F., et al., Serum amyloid A and haptoglobin concentrations are
increased in plasma of mares with ascending placentitis in the absence of changes

100

54.
55.
56.
57.

58.

59.

60.
61.

62.
63.
64.

65.
66.

67.

68.
69.
70.
71.

in peripheral leukocyte counts or fibrinogen concentration. Am J Reprod
Immunol, 2014. 72(4): p. 376-85.
Hong, C.B., et al., Etiology and pathology of equine placentitis. J Vet Diagn
Invest, 1993. 5(1): p. 56-63.
Canisso, I.F., Studies on Equine Placentitis. 2014.
Corbin, C.J., et al., Equine 5alpha-reductase activity and expression in
epididymis. J Endocrinol, 2016. 231(1): p. 23-33.
Ousey, J., Rossdale PD, Palmer L, Granger L, Houghton E, Fowden AL, Effect of
5alpha-reductase blockade on progestagen metabolism and parturition in mares.
Journal of Reproduction, 2001. 27(11): p. 11-12.
Giguere, S. and D. Vaillancourt, Evaluation of two qualitative enzyme
immunoassays for the rapid assessment of progesterone in equine plasma. Can
Vet J, 1994. 35(10): p. 643-5.
Toishi, Y., et al., Evaluation of the PATHFAST Chemiluminescent Enzyme
Immunoassay for Measuring Progesterone in Whole Blood and Serum of Mares. J
Equine Sci, 2013. 24(3): p. 47-51.
Yalow, R.S. and S.A. Berson, Immunoassay of endogenous plasma insulin in
man. 1960. Obes Res, 1996. 4(6): p. 583-600.
Gorbman, A., ULTRAFILTRATION OF URINE FOR COLLECTION AND
BIOLOGICAL ASSAY OF EXCRETED HYPOPHYSEAL HORMONES.
Endocrinology, 1945. 37(3): p. 177-190.
Butt, W.R., et al., Assays of gonadotrophins and their applications. Proc R Soc
Med, 1975. 68(2): p. 71-3.
Wheeler, M.J., Hormone Assays in Biological Fluids. Second edition ed. 2013,
New York: Springer Science + Business Media. 310.
Brugger, N., et al., Quantitative determination of progesterone (P4) in canine
blood serum using an enzyme-linked fluorescence assay. Reprod Domest Anim,
2011. 46(5): p. 870-3.
Brown J., W.S., Steinman K., ENDOCRINE MANUAL FOR REPRODUCTIVE
ASSESSMENT OF DOMESTIC AND NON-DOMESTIC SPECIES.
Leenaars, M. and C.F.M. Hendriksen, Critical Steps in the Production of
Polyclonal and Monoclonal Antibodies: Evaluation and Recommendations. ILAR
Journal, 2005. 46(3): p. 269-279.
Lipman, N.S., et al., Monoclonal versus polyclonal antibodies: distinguishing
characteristics, applications, and information resources. Ilar j, 2005. 46(3): p.
258-68.
Chou, S.F., Production and purification of monoclonal and polyclonal antibodies
against cholera toxin. Hybrid Hybridomics, 2004. 23(4): p. 258-61.
Lovell, J.D., et al., Endocrine patterns of the mare at term. J Reprod Fertil Suppl,
1975(23): p. 449-56.
Kohler, G. and C. Milstein, Continuous cultures of fused cells secreting antibody
of predefined specificity. Nature, 1975. 256(5517): p. 495-497.
Knott, K.K., et al., Fecal estrogen, progestagen and glucocorticoid metabolites
during the estrous cycle and pregnancy in the giant anteater (Myrmecophaga
tridactyla): evidence for delayed implantation. Reprod Biol Endocrinol, 2013. 11:
p. 83.
101

72.

73.

74.
75.
76.

77.
78.
79.
80.
81.
82.

83.

84.

85.

86.

87.

88.

Taieb, J., et al., Testosterone measured by 10 immunoassays and by isotopedilution gas chromatography-mass spectrometry in sera from 116 men, women,
and children. Clin Chem, 2003. 49(8): p. 1381-95.
Boudou, P., et al., Comparison of progesterone concentration determination by
12 non-isotopic immunoassays and gas chromatography/mass spectrometry in 99
human serum samples. J Steroid Biochem Mol Biol, 2001. 78(1): p. 97-104.
Johnson M, P.H., Antibody Quality Mater Methods, 2014. 4(572).
Nagy, P., et al., Progesterone determination in equine plasma using different
immunoassays. Acta Vet Hung, 1998. 46(4): p. 501-13.
Squires, E.L., B.C. Wentworth, and O.J. Ginther, Progesterone concentration in
blood of mares during the estrous cycle, pregnancy and after hysterectomy. J
Anim Sci, 1974. 39(4): p. 759-67.
Sandra P., V.G., Lynen F., Schelfaut M. , Considerations on column selection and
operating conditions for LC-MS. LC GC EUROPE, 2001. 12: p. 8-21.
Mendelson, C.R., Minireview: Fetal-Maternal Hormonal Signaling in Pregnancy
and Labor. Molecular Endocrinology, 2009. 23(7): p. 947-954.
Thorburn, G.D., A speculative review of parturition in the mare. Equine Vet J
Suppl, 1993(14): p. 41-9.
Belelli, D. and J.J. Lambert, Neurosteroids: endogenous regulators of the
GABA(A) receptor. Nat Rev Neurosci, 2005. 6(7): p. 565-75.
Bicikova, M., et al., Two neuroactive steroids in midpregnancy as measured in
maternal and fetal sera and in amniotic fluid. Steroids, 2002. 67(5): p. 399-402.
Nguyen, P.N., et al., Changes in 5alpha-pregnane steroids and
neurosteroidogenic enzyme expression in the perinatal sheep. Pediatr Res, 2003.
53(6): p. 956-64.
Canisso, I.F., et al., Decreasing pH of mammary gland secretions is associated
with parturition and is correlated with electrolyte concentrations in prefoaling
mares. Vet Rec, 2013. 173(9): p. 218.
Contractor, P., et al., Reliable and sensitive determination of dutasteride in human
plasma by liquid chromatography-tandem mass spectrometry. Biomed
Chromatogr, 2013. 27(9): p. 1168-76.
Olsen, E.A., et al., The importance of dual 5alpha-reductase inhibition in the
treatment of male pattern hair loss: results of a randomized placebo-controlled
study of dutasteride versus finasteride. J Am Acad Dermatol, 2006. 55(6): p.
1014-23.
Gisleskog, P.O., et al., The pharmacokinetic modelling of GI198745 (dutasteride),
a compound with parallel linear and nonlinear elimination. Br J Clin Pharmacol,
1999. 47(1): p. 53-8.
Dong, E., et al., Brain 5alpha-dihydroprogesterone and allopregnanolone
synthesis in a mouse model of protracted social isolation. Proc Natl Acad Sci U S
A, 2001. 98(5): p. 2849-54.
Wiebe, J.P., L. Souter, and G. Zhang, Dutasteride affects progesterone
metabolizing enzyme activity/expression in human breast cell lines resulting in
suppression of cell proliferation and detachment. J Steroid Biochem Mol Biol,
2006. 100(4-5): p. 129-40.

102

89.

90.

91.

92.
93.

94.
95.
96.
97.

98.

99.

100.

101.
102.

Clark, R.V., et al., Marked suppression of dihydrotestosterone in men with benign
prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin
Endocrinol Metab, 2004. 89(5): p. 2179-84.
Roehrborn, C.G., et al., Efficacy and safety of a dual inhibitor of 5-alphareductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.
Urology, 2002. 60(3): p. 434-41.
Han, X., et al., Localisation of 15-hydroxy prostaglandin dehydrogenase (PGDH)
and steroidogenic enzymes in the equine placenta. Equine Vet J, 1995. 27(5): p.
334-9.
Canisso, I.F., et al., Changes in maternal androgens and oestrogens in mares with
experimentally induced ascending placentitis. Equine Vet J, 2016.
Munro, C. and G. Stabenfeldt, Development of a microtitre plate enzyme
immunoassay for the determination of progesterone. J Endocrinol, 1984. 101(1):
p. 41-9.
Hewett, P. and G.H. Ganser, A comparison of several methods for analyzing
censored data. Ann Occup Hyg, 2007. 51(7): p. 611-32.
Ousey, J.C., Peripartal endocrinology in the mare and foetus. Reprod Domest
Anim, 2004. 39(4): p. 222-31.
Holtan, D.W., et al., Effect of ovariectomy on pregnancy in mares. J Reprod Fertil
Suppl, 1979(27): p. 457-63.
Daels, P.F., et al., Effect of progesterone on prostaglandin F2 alpha secretion and
outcome of pregnancy during cloprostenol-induced abortion in mares. Am J Vet
Res, 1996. 57(9): p. 1331-7.
Lampinen-Salomonsson, M., et al., Detection of altrenogest and its metabolites in
post administration horse urine using liquid chromatography tandem mass
spectrometry--increased sensitivity by chemical derivatisation of the glucuronic
acid conjugate. J Chromatogr B Analyt Technol Biomed Life Sci, 2006. 833(2):
p. 245-56.
McConaghy, F.F., et al., Studies of the pharmacokinetic profile, in vivo efficacy
and safety of injectable altrenogest for the suppression of oestrus in mares. Aust
Vet J, 2016. 94(7): p. 248-55.
Palm, F.M., et al., Concentrations of altrenogest in plasma of mares and foals and
in allantoic and amniotic fluid at parturition. Theriogenology, 2010. 74(2): p.
229-35.
Bland, J.M. and D.G. Altman, Measuring agreement in method comparison
studies. Stat Methods Med Res, 1999. 8(2): p. 135-60.
Squires, E.L., et al., Relationship of altrenogest to ovarian activity, hormone
concentrations and fertility of mares. J Anim Sci, 1983. 56(4): p. 901-10.

103

Vita
Michelle Arelia Ann Wynn
Academic Degrees
2011………...………………………………………………………..Associate of Science,
Bluegrass Community and Technical College, Lexington, Kentucky
2013……………………………………………..….Bachelor of Science, Animal Science,
University of Kentucky, Lexington, Kentucky
Experience
June 2014-May 2017…………………………………...…Gluck Equine Research Center,
Department of Veterinary Science
University of Kentucky, Lexington, Kentucky
Graduate Research Assistant

Abstracts
M.A.A. Wynn, E.L. Legacki, A.J. Conley, S.A. Loux, A. EstellerVico, S.D. Stanley, E.L. Squires, M.H.T. Troedsson, and others.
Determination of peripheral progestin concentrations in the late
pregnant mare based upon immunoassays and liquid
chromatography-tandem mass spectrometry. Journal of Equine
Veterinary Science, Vol. 35, Issue 5, p441–442
M. Wynn*, E. Legacki, A. Conley, S. Loux, A. Esteller-Vico, S. Stanley, E. Squires, M.
Troedsson, and B. Ball Inhibition of 5α-reductase during late gestation in the mare
Reproduction, Fertility and Development 28(2) 163-163
https://doi.org/10.1071/RDv28n2Ab67
Published: 3 December 2015
Michelle Wynn, BS, Carleigh Fedorka, BS, Barry A. Ball, DVM, PhD, DACT#, Carolyn
Cray, PhD, Igor Canisso, DVM, PhD, DACT, DECAR, Thomas Curry, Jr. PhD, Laura
Kennedy DVM, DACVP, Mats Troedsson DVM, PhD, DACT, DECAR, Edward L.
Squires, PhD. A prospective case-control study of biomarkers for feto-placental wellbeing in the mare: Research Abstract. AAEP conference, Orlando, Florida, 2016

104

Publications
Reproduction. 2016 Oct;152(4):323-31. doi: 10.1530/REP-16-0227. Progestin
withdrawal at parturition in the mare. Legacki EL1, Corbin CJ1, Ball BA2, Wynn M2,
Loux S2, Stanley SD3, Conley AJ4.
Presentations
Determination of peripheral progestin concentrations in the late pregnant mare
based upon immunoassay and liquid chromatography - tandem mass
spectrometry
Conference of the Center for Clinical and Translational Science, 34th Annual Symposium
in Women’s Health and Reproductive Science. April 2015, Lexington, KY.
Determination of peripheral progestin concentrations in the late pregnant mare based
upon immunoassays and liquid chromatography-tandem mass spectrometry
M.A.A. Wynn, E.L. Legacki, A.J. Conley, S.A. Loux, A. Esteller-Vico, S.D. Stanley,
E.L. Squires, M.H.T. Troedsson, and others
Equine Science Symposium. May 2015, St. Pete Beach, FL
A prospective case-control study of biomarkers for feto-placental well-being in the
mare
Conference of the Center for Clinical and Translational Science, 35th Annual Symposium
in Women’s Health and Reproductive Science. April 2016, Lexington, KY.
Inhibition of 5α-reductase during late gestation in the mare
M. Wynn*, E. Legacki, A. Conley, S. Loux, A. Esteller-Vico, S. Stanley, E. Squires, M.
Troedsson, and B. Ball (Abstract 67)
International Embryo Transfer Society. January 2016, Louisville, KY
Publications in Preparation
Michelle Wynn, Barry A. Ball, Erin Legacki, Alan Conley, Shavahn Loux, John May,
Alejandro Esteller-Vico, Scott Stanley, Kirsten Scoggin, Edward Squires, Mats
Troedsson. Inhibition of 5α-reductase alters pregnane metabolism during late gestation in
the mare.
Michelle Wynn, Barry A. Ball, John May, Alejandro Esteller-Vico, Igor Canisso, Edward
Squires, Mats Troedsson. Changes in maternal pregnane concentrations in mares with
experimentally induced ascending placentitis.
Michelle A. Wynn, Erin L. Legacki, Alan J. Conley, Shavahn C. Loux, Alejandro
Esteller-Vico, Scott D. Stanley, Thomas E. Curry, Jr., Edward L. Squires, Matts H.
Troedsson, Barry A. Ball. A comparison of progesterone assays for determination of
peripheral pregnane concentrations in the late pregnant mare

105

